The effect of melatonin treatment on doxorubicin-induced skeletal muscle atrophy within a cancer model by Isaacs, Ashwin Wayne
i | P a g e
THE EFFECT OF MELATONIN TREATMENT ON 
DOXORUBICIN-INDUCED SKELETAL MUSCLE ATROPHY 
WITHIN A CANCER MODEL 
by 
Ashwin Wayne Isaacs 
Dissertation presented for the degree of 
Doctor of Physiological Sciences in the 
Faculty of Science at 
Stellenbosch University 
Supervisor: Prof Anna-Mart Engelbrecht 
Co-supervisor: Prof Ben Loos 
Prof Kathryn Helen Myburgh 
December 2018 
ii | P a g e
Declaration 
By submitting this dissertation electronically, I declare that the entirety of the work contained 
therein is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will not 
infringe any third party rights and that I have not previously in its entirety or in part submitted 




Stellenbosch University  https://scholar.sun.ac.za
iii | P a g e  
 
Summary 
Background  and  Aim:  Skeletal  muscle  atrophy  is  a  major  concern  in  patients  suffering  with 
malignancy. Chemotherapeutic agents, such as doxorubicin (DOX), can further exacerbate this loss of 









Methods: Female Sprague‐Dawley  rats were  inoculated with  LA7  cancer  cells and were  randomly 
assigned to six groups: Control, Tumour control (TCON), Vehicle control (VEH), MLT, DOX and DOX + 
MLT (DM). Prophylactic treatment of MLT (6 mg/kg) was administered in drinking water daily and rats 
received  three  intraperitoneal  injections  of DOX  (4 mg/kg,  3  times  at  3‐day  intervals).  Following 
sacrifice blood samples (whole blood counts) and skeletal muscle tissue were collected for histological, 
immunoblot, antioxidant capacity and immunofluorescence analyses. Furthermore, C2C12 myoblasts 
grown  to confluency and differentiated  into myotubes were pretreated with MLT  (50 nM)  for 48h 
followed  by  DOX  treatment  (0.8  µM)  for  24h.  The  effect  of MLT  treatment  on  C2C12 myotube 
diameter, mitochondrial  reactive oxygen species  (mtROS) production, sirtuin  levels and autophagy 
activity was then assessed.   
 
Results: DOX  treatment  significantly  reduced animal weight  (279.1 ± 21.34 g  vs. 222.2 ± 20.40 g, 
p˂0.0001)  compared  to DM weight  (281.5 ± 7.11 g vs. 284.0 ± 6.53 g) and gastrocnemius muscle 
weight  (1.4 ± 0.13 g vs. 0.99 ± 0.076 g, p˂0.0001) and cross sectional area  (CSA), while  increasing 
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markers  of muscle  degradation  compared  to MLT  treated  groups.  Serum myoglobin  levels were 
significantly elevated in the DOX group compared to the DM group (572.6 ± 444.19 ng/mL vs. 218.2 ± 
83.66  ng/mL,  p˂0.0001);  while,  white  &  red  blood  cell  counts  (WBC  &  RBC)  were  significantly 
decreased in the DOX group compared to the MLT treated groups respectively (2.06 ± 1.59 x 109L‐1 vs. 
4.13 ± 1.56 x 109L‐1 & 4.00 ± 1.52 x 1012L‐1 vs. 5.66 ± 1.03 x 1012L1, p˂0.0001). Furthermore, MLT 
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effektiewe  rol  van melatonien  as  ‘n moontlik  terapeutiese middel  om  doxorubicin‐geïnduseerde 
spiertoksisiteit in kankerpasiënte te verminder, dien as rasionaal vir die in vivo studie en die in vitro 
studie  is  gedoen  om  meganistiese  aspekte  van  die  werking  van  die  terapie  meer  in  diepte  te 
ondersoek. 
Metodes: Vroulike Sprague‐Dawley  rotte  is met LA7 selle geïnokuleer en  is  in ses groepe verdeel: 
Kontrole, Tumor Kontrole (TCON), Oplosmiddel Kontrole (VEH), MLT, DOX en DOX + MLT (DM). Die 
rotte  is profilakties met MLT  (6 mg/kg), wat daagliks  in hul drinkwater toegedien  is, behandel. Die 
rotte het ook drie intraperitoneale DOX (4 mg/kg, 3 keer met 3 dae intervalle) inspuitings ontvang. Na 
die  eksperimentele  tydperk,  is  bloedmonsters  (heelbloedtellings)  en  skeletspier  versamel  vir 
histologie,  immunoblot, antioksidant kapasiteit en  immunofluoresensie bepalings. Verder  is C2C12 
mioblaste gedifferensieer in miobuise en met MLT (50 nM) behandel vir 48 uur voordat 0.8 M DOX 




222.2 ± 20.40  g, p˂0.0001)  asook die gastrocnemius  spiermassa  (1.4 ± 0.13  g  vs. 0.99 ± 0.076  g, 
p˂0.0001) en deursnitarea (CSA) in vergelyking met die DM groep (281.5 ± 7.11 g vs. 284.0 ± 6.53 g), 
terwyl merkers van atrofie verhoog is in vergelyking met die MLT groepe. Serum myoglobien vlakke is 
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4.00  ±  1.52  x  1012L‐1  vs.  5.66  ±  1.03  x  1012L‐1,  p˂0.0001).  Verder  het  MLT  behandeling  die 
intramuskulêre antioksidant kapasiteit, mitokondriale biogenese en aantal satellietselle insiggewend 
verhoog.  In  vitro DOX  behandeling  het miobuis  atrofie  asook mitokondriale  ROS  vlakke  verhoog, 
terwyl hierdie effekte insiggewend verlaag is in die groepe wat vooraf met melatonien behandel is. 
Bespreking: Die  toename  in die diere  se gewig, spier  tot  liggaamsgewig  ratio en spierdeursnitarea 
asook die verlaging  in mioglobienvlakke  in die MLT behandelde groepe  in vergelyking met die DOX 
groepe,  bewys  dat  MLT  die  liggaam  teen  DOX‐geïnduseerde  atrofie  beskerm.  Verder  het  MLT 
behandeling  ook  die  sirkulerende  vlakke  van  WBS  &  RBS  verhoog  in  vergelyking  met  die  DOX 
behandeling, terwyl apoptose verminder het en satellietselle toegeneem het, wat aanduidend is van 
MLT  se  rol  in  spierherstel.  Die  in  vitro  studie  dui  aan  dat  DOX‐geïnduseerde  miobuis  atrofie 
voorafgegaan is deur ‘n toename in mitokondriale ROS. 
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Chapter 1:   
1.1 Introduction 
Cancer cachexia is a major concern in patients suffering from malignancy. It is 
reported that up to 50% of cancer patients experience a progressive loss of skeletal 
muscle (Tisdale 2009), which occurs due to the depression of muscle protein synthesis 
combined with an increase in protein degradation (Lorite et al. 1998). This reduction 
in muscle mass affects various aspects of muscle function and is associated with 
muscle weakness and fatigue (Roberts et al. 2013), with consequently reduced quality 
of life (Aversa et al. 2017, Penna et al. 2018). Loss of muscle mass is even associated 
with mortality, emphasizing the clinical significance of this condition (Morrow et al. 
2002, Roscoe et al. 2002, and van Norren et al. 2009). Although many cancer patients 
suffer from this condition, there are no available therapies routinely used to reduce 
muscle loss. 
In addition to the disease mechanisms, chemotherapeutic agents, such as 
doxorubicin, can further exacerbate the loss of skeletal muscle (Morrow et al. 2002, 
Burckart et al. 2010, Gilliam and St Clair 2011). Doxorubicin, a standard antineoplastic 
anthracycline, has shown great success in the treatment of several malignant and solid 
tumours such as breast cancer (Koka et al. 2010, Gilliam et al. 2011, Wergeland et al. 
2011), however, its benefits are limited due to its cytotoxic side effects on non-targeted 
tissue, such as skeletal muscle (Burckart et al. 2010, Gilliam and St Clair 2011, Gilliam 
et al. 2012).  
Loss of skeletal muscle is characterised by a shift towards protein degradation. Two 
highly conserved pathways, namely the ubiquitin-proteasomal pathway and the 
autophagy pathway mediate protein degradation in skeletal muscle (Bonaldo and 
Sandri 2013). In normal skeletal muscle the ubiquitin-proteasomal pathway is 
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constitutively active and is responsible for the turnover of most soluble and myofibrillar 
proteins (Solomon and Goldberg 1996). During muscle atrophy the ubiquitin-
proteasomal pathway activity is significantly elevated through the transcriptional 
activation of ubiquitin; various proteasomal subunit genes; and muscle specific 
ubiquitin ligases, MAFbx and MuRF1 (Mammucari et al. 2007). 
The mechanism by which doxorubicin induces toxicity in skeletal muscle remains 
largely unexplored. However, it was demonstrated in a recent study that a reduction 
in differentiated C2C12 myotube width occurred following doxorubicin treatment, 
which was accompanied by increased expression of markers of apoptosis (cleaved 
caspase3) and atrophy (atrogin-1/MAFbx) (Gilliam et al. 2012). The authors further 
demonstrated that the inhibition of reactive oxygen species (ROS) preserved myotube 
size and concluded that doxorubicin acts via mitochondrial ROS to stimulate 
catabolism of myotubes.  
Furthermore, Smuder et al. (2011), provided evidence that systemic doxorubicin 
administration in rats increased the expression of various autophagy markers in soleus 
muscle. During the autophagic process, portions of the cytoplasm and cell organelles 
are isolated into vacuoles, termed autophagosomes which then fuse with lysosomes 
where autophagosome contents are digested by lysosomal hydrolases (Mizushima et 
al. 2008).  
Various strategies have been explored in attempts to reduce doxorubicin-induced 
muscle atrophy. These include physical activity (Smuder et al. 2011), synthesis of 
alternative anthracycline analogues (Petrioli et al. 2008), as well as the use of 
nanoparticles (Dong et al. 2009) and liposomes (Mrozek et al. 2005) as novel, more 
targeted drug delivery systems. Nevertheless, the use of doxorubicin with its 
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associated negative side effects persists (Hayward et al. 2013). Therefore, it is of 
utmost importance to identify an adjuvant therapy capable of alleviating the effects of 
doxorubicin on skeletal muscle. Ideally, such an adjuvant should be multi-acting to 
alleviate multiple mechanisms inducing side effects. 
Melatonin (N-acetyl-5-methoxytryptamine) is a naturally occurring pleiotropic hormone 
primarily secreted by the pineal gland (Tasdemir et al. 2012). Its initial function is 
hypothesised to serve as antioxidant in Cyanobacteria which first appeared on earth 
approximately 3.5 billion years ago (Manchester et al. 2015). This hormone influences 
almost all cell processes and has secondary functions which include oncostatic 
properties (Proietti et al. 2013), anti-inflammatory (Laste et al. 2012), analgesic (Laste 
et al. 2012), and neuroprotective characteristics (Srinivasan et al. 2008, Robertson et 
al. 2013). Numerous studies have revealed the efficacy of melatonin in the 
suppression of neoplastic growth in a variety of tumours (Proietti et al. 2013). 
Additionally, it has been found to be beneficial as adjuvant therapy when used in 
conjunction with chemotherapeutic agents in patients suffering from breast cancer and 
melanoma (Kilic et al. 2013).  
Interestingly, a literature search revealed only three in vivo studies investigating the 
effects of melatonin treatment in the prevention of skeletal muscle atrophy. The first 
study showed that melatonin treatment maintained soleus muscle fibre diameter in an 
in vivo rat castration model (Oner et al. 2008). It was found in two more recent studies 
that melatonin treatment prevented skeletal muscle atrophy in a contusion spinal cord 
injury model (Park et al. 2012) and in a stroke-induced skeletal muscle atrophy model 
(Lee et al. 2012). The mechanisms of action uncovered by these studies will be 
addressed later in section 2.7.6. 
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1.2 Significance of the study 
Evidence from observational data over the years alludes to a potential role for 
melatonin in cancer prevention. Furthermore, melatonin has previously been found to 
prevent muscle wasting both in vitro (Park et al. 2013) and in vivo (Oner et al. 2008, 
Lee et al. 2012) in various atrophy models. Therefore, it could in future play a dual role 
by allowing for reduction of the chemotherapeutic agent dose and reducing some of 
the side effects. However, to the best of our knowledge this is the first study to 
investigate the effects of melatonin on skeletal muscle in a cancer model.  
1.3 Hypothesis 
Based on previous research, we hypothesise, that melatonin treatment will prevent 
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Chapter 2: Literature Review 
2.1 Cancer cachexia 
2.1.1 What is cancer cachexia? 
The word cachexia originates from the Greek words ‘kakos’ meaning bad and ‘hexis’ 
meaning condition. The Greek, Hippocrates, described the condition in the third 
century before Christ (BC) and associated it with a poor prognosis. The cachectic 
condition is characterised by loss of appetite, anorexia, oedema, anaemia, weakness, 
inflammation and gradual atrophy of adipose tissue and skeletal muscle (Tisdale 2009, 
Fearon et al. 2012, Chen et al. 2015, Xi et al. 2016), all of which cannot be reversed 
with nutritional intervention in the face of continuation of the disease process.   
Cachexia is seen in patients with various chronic diseases, such as diabetes, multiple 
sclerosis, chronic obstructive pulmonary disease, congestive heart failure, 
tuberculosis, acquired immune deficiency syndrome (AIDS), and cancer (Graul et al. 
2016, von Haehling et al. 2016). The condition is easily recognisable in its advanced 
stage but is much more difficult to predict for the purposes of early intervention. In the 
past various definitions of cachexia were used in different studies in the literature. The 
more general classification of cachectic patients is a 10% weight-loss from pre-illness 
weight (Feliu et al. 1992). Cancer cachexia as defined by McDonald et al. (2003)  is a 
syndrome of muscle and fat wasting as a direct consequence of tumour factors and 
has been described by Fearon et al. (2012) as a state of ‘autocannibalism’ in which 
the tumour survives at the expense of the host.  
2.1.2 Skeletal muscle atrophy as a consequence of cancer cachexia 
Cancer is a leading cause of morbidity and mortality globally, with approximately 14 
million new cases diagnosed and cancer related deaths in 2012 totalling 8.2 million 
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(Sorensen et al. 2016). It is reported that up to 50% of all cancer patients, as well as 
the majority of patients with advanced diseases, experience cachexia (Tisdale 2009; 
Fearon et al. 2012); furthermore approximately 30% of cancer patients die as a direct 
result of cancer cachexia (Mu et al. 2016). Cancer cachexia affects both physiological 
and pathological conditions which dictate variation of skeletal muscle mass and 
individual muscle fibre size (Schiaffino et al. 2013).  
Skeletal muscle represents more or less 40% of the total body weight, making it the 
most abundant tissue of the human body, regulating both energy availability and 
expenditure (Frontera and Ochala 2015). During the physiological state there exists 
homeostatic balance between protein synthesis and degradation (Rothman 2010). 
Skeletal muscle atrophy as consequence of cancer cachexia occurs when protein 
degradation exceeds protein synthesis resulting in the net loss of protein. Patients 
experience subsequent unexplained weight loss, muscle weakness, fatigue, 
decreased mobility and quality of life, which eventually leads to mortality (Argiles et al. 
2015, Mueller et al. 2016). The unexplained weight loss and fatigue are often the 
primary reasons patients seek medical consultation, since nutritional interventions 
have been shown to be ineffective at combating the cachectic state. Current therapies 
used to treat cachexia are also ineffective and the main reasons (Burckart et al. 2010) 
reside in the facts that the disease state mechanisms are multimodal and not clearly 
defined. Several mediators have been identified, including pro-inflammatory cytokines 
(TNF-α, IFNγ, IL-6) as well as the tumour-secreted proteolysis-inducing factor (PIF), 
which enhance both autophagic-lysosomal and proteasome-mediated muscle 
catabolism (Noguchi et al. 1996, Tisdale 2008, Fearon et al. 2012). Up-regulation of 
muscle specific ubiquitin-ligases, namely muscle RING finger-containing protein 1 
(MuRF1) and muscle atrophy Fbox protein (MAFbx), alter the balance between 
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synthesis and degradation of muscle protein (Costelli et al. 2006). Several 
transcription factors (FoxO, NF-kB and AP-1) have been implicated in muscle wasting 
(Hasselgren 2007). Reduced testosterone concentrations have also been reported in 
cachectic patients (Feld and Hirschberg 1996). 
Increased protein degradation may be due to both an increase in ubiquitin-proteasome 
pathway and lysosomal activity, while protein synthesis mechanisms are decreased. 
It is important to note that factors and processes contributing to muscle synthesis or 
degradation may differ depending on cancer type and model used for scientific 
investigation. Furthermore, human biology in health/disease states is complex and 
multiple signalling pathways are involved in muscle wasting which is evident in cancer 
cachexia. Herewith certain mechanisms which may contribute to muscle tissue 
degradation in cancer cachexia are described below. 
2.2 Mechanisms of cancer cachexia 
Tisdale 2009, describes three main proteolytic pathways responsible for the 
degradation of skeletal muscle proteins, which include the: i) ubiquitin-proteasome 
pathway (UUP), ii) lysosomal/autophagy system, and iii) calcium-activated system. In 
conjunction with these three pathways, some of the main molecular mechanisms were 
described: iv) caspases, v) Forkhead box (FoxO) of transcription factors and vi) 
proteolysis-inducing factor (PIF). 
2.2.1 The ubiquitin-proteasome pathway (UPP) 
The ubiquitin-proteasome pathway, is an ATP-dependent system working in co-
ordination with the calpain enzyme to degrade muscle myofilaments (Hasselgren and 
Fischer 2001). The UPP catalyses the breakdown of most long-lived proteins and 
removes proteins which have been damaged by genetic alterations or by thermal or 
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oxidative stress (Kedar et al. 2004). This system is characterized by the polyubiquitin 
chain of three enzymes: E1 - Ub-activating enzyme; E2 - Ub-conjugating enzyme and 
E3 - Ub-protein ligase.  
The protein substrate is tagged by the ubiquitin chain via a reaction sequence 
consisting of a series of enzymes involving E1 (ubiquitin activation). This system has 
been shown to be active in various in vivo models of atrophy such as denervation, 
immobilization, muscle unloading (Bodine et al. 2001), and cancer (MacDonald 2003). 
In fact, in vivo cancer cachexia model studies along with studies of cancer patients, 
advocate that the UPP may have the biggest role to play in myofibrillar protein 
degradation (Khal et al. 2005). The muscle-specific E3 ubiquitin ligases, namely, 
MuRF1 and MAFBx/atrogin-1 were shown to be highly upregulated in many animal 
models of muscle wasting, including cancer cachexia (Bodine et al. 2001, Gomes et 
al. 2001). MAFBx promotes degradation of a vital muscle transcription factor, 
regulating muscle differentiation, MyoD (Tintignac et al. 2005), while MuRF1 can 
interact with and control important structural proteins, including myosin heavy chain 
(Clarke et al. 2007), troponin-1 (Kedar et al. 2004), myosin light chain and myosin 
binding protein C (Cohen et al. 2009). The overexpression of MAFbx in myotubes 
resulted in reduced myotube size in vitro, while mice lacking either MAFbx or MuRF1 
were resistant to atrophy (Bodine et al. 2001). Furthermore, knockdown of MAFBx has 
been shown to attenuate muscle loss during fasting (Cong et al. 2010).   
However, literature on the contribution of E3 ligases to muscle atrophy has been 
controversial. Investigations in patients presenting with atrophy caused by a myriad of 
diseases have demonstrated both increased and decreased expression of MuRF1 and 
MAFBx/atrogin-1 (Edstrom et al. 2006, Leger et al. 2006, Doucet et al. 2007, de Palma 
et al. 2008, Fredriksson et al. 2008, Salanova et al. 2008). Furthermore, investigations 
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of UPP activity have demonstrated that lung cancer patients presenting with cachexia 
had similar levels of UPP activity compared to controls (Op den Kamp et al. 2012). 
Although the evidence on UPP activity in cancer cachexia seems to be conflicting, the 
timing of investigation, stage of cachectic progression and tumour type are factors that 
need to be taken into consideration to clearly establish the role of the UPP in cancer 
cachexia. 
2.2.2 The lysosomal/autophagy system 
Macroautophagy/autophagy is a highly conserved process occurring at basal levels of 
all eukaryotes (Masiero et al. 2009) executing the degradation of intracellular proteins 
and cell receptors (Hasselgren and Fischer 2001), damaged organelles and 
intracellular pathogens (Mizushima et al. 2008). Under physiological conditions, basal 
autophagy is responsible for the degradation of redundant cellular constituents which 
are then used as additional energy sources for different metabolic processes 
(Uchiyama et al. 2008) and thus protects against the aggregation of components which 
may become cytotoxic (Button et al. 2017 and Inguscio et al. 2012). However, under 
conditions of cellular stress, such as hypoxia and nutrient deprivation, autophagy 
activity is enhanced and non-essential cell components may be broken down to fuel 
essential metabolic processes as a mechanism of protection (Inguscio et al. 2012). 
The protein Beclin 1 is a central regulator of autophagy and acts during the initiation 
stage of autophagy by manufacturing a double membrane structure to form the 
autophagosome, which surrounds cytoplasmic components targeted for degradation 
(Mizushima et al. 2008). Autophagosomes fuse with the lysosomes, whereafter the 
membrane and content of the autophagosome vesicles are degraded. There are more 
than 30 known genes regulating autophagy in yeast, many of which are shared 
commonly with mammals (Atg genes) (Ravikumar et al. 2010), whilst expressed 
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autophagy specific proteins (Atg proteins) regulate the different processes of 
autophagy (Mizushima et al. 2010). 
This process follows a distinct sequence of events, namely:  
1) Induction of autophagy: This step includes the formation of phagophores which 
involves the specific recruitment of proteins into forming autophagosomal membranes 
from sources such as endoplasmic-reticulum or golgi complexes. Recruited proteins 
include p62, an ubiquitin cargo-binding protein, which acts as a partial selective 
receptor for different substrates (Lippai and Lőw 2014). The most common triggers of 
autophagy are nutrient starvation and hypoxia. 
2) Autophagosome expansion and formation: This includes the elongation of 
formed phagophores and is mediated by a collection of autophagy specific genes (Pyo 
et al. 2012). During autophagosome formation, LC3-I is converted to LC3-II; LC3-II 
promotes membrane tethering and thus associates with the autophagosome, which is 
typically a double-membraned organelle. Activated Atg12 covalently binds to Atg5 and 
this formed complex then conjugates with Atg16L1. Next, LC3 is cleaved to form LC3-
I in the cytosol which then conjugates to phosphatidylethanolamine (PE) to form LC3-
II via the actions of Atg3 and Atg7. LC3-II remains associated with the 
autophagosomal membrane, and as such is a valuable molecular marker for 
autophagy (Ravikumar et al.2010). The protein, p62, another molecular marker for 
autophagy, is involved in the targeting of poly-ubiquitinated proteins towards 
autolyosomes for degradation (Barth et al. 2010). 
3) Fusion: The autophagosomal membrane is formed from intracellular membranous 
structures such as the endoplasmic reticulum (ER), mitochondria and the Golgi 
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apparatus. The merger of an autophagosome with a lysosome to form an 
autolysosome which is a degrading structure now separate from the cytoplasm.  
4) Degradation: In this step, the targeted cytoplasmic components are degraded by 
acidification, Fig.2.1 (Lee et al. 2012). The inner membrane of the autophagosome 
and the cytoplasm-derived materials contained in the autophagosome are then 
degraded by lysosomal/vacuolar hydrolases.  
 
Figure 2.1: The cellular processes during autophagy. Image adapted from Lee et al (2012). 
Lysosomes are vitally important in the autophagic process; are comprised of a single-
lipid bilayer membrane which encapsulates several types of hydrolases that enable 
the degradation of variety of substrates (Settembre et al. 2013). Transport proteins 
residing in the membrane of lysosomes facilitate the passage of both intra- and 
extracellular proteins as well as acidification of the lumen and fusion with other 
structures.  
Alterations in the autophagy programme in skeletal muscle are associated with a 
number of myopathies, where the excessive activation of autophagy enhances 
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skeletal muscle loss (Wang et al. 2005, Mammucari et al. 2007, Zhao et al. 2007, 
Dobrowolny et al. 2008). Maserio et al. (2009) carried out an in vivo “loss of function” 
study where a muscle-specific autophagy gene, Atg7, was deleted in mice. The 
investigators found that this deletion resulted in profound muscle loss and muscle 
weakness. Furthermore, in animal models of cancer, autophagy has been associated 
with both skeletal muscle and cardiac muscle pathology. An elevation in total 
lysosomal protease activity has been observed in muscles of tumour bearing rats 
(Greenbaum and Sutherland 1983). A study by Cosper and Leinwand (2011) 
demonstrated that autophagy, independent of UPP activity, was associated with 
cardiac atrophy of myofibrillar and sarcomeric proteins in tumour bearing mice.  
Human studies revealed increased cathepsin B (a lysosomal cysteine protease) 
mRNA in skeletal muscle biopsies from lung cancer patients (Jagoe et al. 2002), with 
higher expression levels in early versus late stage tumours. UPP activity remained 
unchanged in these patients, leading investigators to conclude that lysosomal 
proteolysis may be upregulated early and that the UPP may be activated later in the 
disease process (Jagoe et al. 2002). A range of autophagy markers at gene and 
protein level were assessed in this comprehensive study. The authors found Beclin-1 
and LC3-IIB protein levels to be increased, suggesting autophagy induction and 
autophagosome formation or autophagosome turnover. 
However, the inhibition of autophagy has also been shown to enhance skeletal muscle 
loss (Masiero et al. 2009). This demonstrates the homeostatic function of autophagy 
in maintaining muscle mass. Similarly, suppression of mitochondrial function has been 
demonstrated to cause significant muscle wasting in adult animals (Romanello et al. 
2010). Many cancer cachexia related studies identify mitochondrial dysfunction as a 
common theme during muscle wasting (Vitorino et al. 2015, Brown et al. 2017). 
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Mitochondria are packaged densely within myofibres where approximately 20% are 
associated with the subsarcolemma area and 80% are associated with the 
intermyofibrillar regions (Vitorino et al. 2015). Therefore, it is perhaps not surprising 
that myofibrillar loss would affect mitochondrial function. Mitochondrial dysfunction is 
an early event during cachexia (Vitorino et al. 2015) and is associated with abnormal 
mitochondrial morphology (Shum et al. 2012), reduced mitochondrial number (Padrao 
et al. 2013, Antunes et al. 2014) and a decrease in mitochondrial biogenesis regulatory 
factors (White et al. 2011).  
A key feature of cancer cachexia is muscle weakness which may indicate that the 
mitochondria in the intermyofibrillar regions may be mostly altered, since they supply 
ATP required for muscle contraction. Calcium ion uptake/regulation by mitochondria 
is critical for ATP production as demonstrated by Eshima et al. (2017). Therefore, it is 
conceivable that a low number of mitochondria could potentially lead to increased 
calcium ion accumulation in the myofibre with subsequent activation of calcium-
activated proteases. On the other hand, an overload of calcium ions within 
mitochondria causes the opening of the permeability transition pore (PTP), the release 
of cytochrome c and subsequent myofibre apoptosis (Naon and Scorrano 2014).  
Furthermore, mitochondrial biogenesis regulatory factor (PGC1-α) coordinates 
mitochondrial fission (division of a single organelle into two or more independent 
structures) and fusion (formation of a single structure from two or more independent 
structures) and is crucial for the maintenance of mitochondrial function, morphology 
and distribution (Scott and Youle 2010, Romanello and Sandri 2013). It was 
demonstrated in a recent study that PGC-1α overexpression improves skeletal muscle 
calcium ion regulation in vivo following contractions (Eshima et al. 2017), providing 
indirect evidence that PGC-1α improves ATP synthesis which was found to be 
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decreased in in vivo models of cancer cachexia (Constantinou et al. 2011, Antunes et 
al. 2014). However, in transgenic mice over-expressing PGC-1α, it was shown that 
muscle wasting persisted in a model of cancer cachexia (Wang et al. 2012).  
Mitochondrial dynamic processes are essential for the maintenance of mitochondria 
integrity and efficiency. This is achieved by preserving a balance between 
mitochondrial fission and fusion. Fusion processes act to extend mitochondrial 
networks and increase energy production and efficiency (Bordi et al. 2017), whereas 
fission divorces dysfunctional or damaged mitochondria (Romanello et al. 2010), 
allowing for their removal through mitophagy (Vitorino et al. 2015). This indicates that 
crosstalk exists between mitophagy and fission processes to remove mitochondria and 
also highlights the danger of excessive fission. These processes are ever changing 
thus allowing for mitochondria to adapt according to the changes in their cellular 
environment (Rambold et al. 2011). 
 
 
Figure 2.2: Possible relationship between mitochondrial fusion, fission, biogenesis and degradation. 
Image obtained from Seo et al. (2010). 
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During prime cellular conditions mitochondria are inclined to form extensive tubules 
and networks which are characteristic of mitochondrial fusion; however this scenario 
may also be present during conditions of stress when mitochondria successfully adapt 
and overcome initial stressors (Rambold et al, 2011). Fusion involves the activity of 
pro-fusion proteins including mitofusin (Mfn) 1 and 2 at the outer mitochondrial 
membrane and the optic atrophic protein 1 (OPA1) (Rambold et al, 2011) at the inner 
mitochondrial membrane. These proteins promote the fusion of membranes of 
adjacent mitochondria. Mitochondrial fusion is a likely contributor to enhanced 
respiration and mitochondrial metabolism and may also act to limit mitophagy and 
apoptosis (Boland, 2013). Alternatively, when mitochondria cannot overcome 
conditions of stress, they become fragmented which is characteristic of fission (Frank 
et al. 2001, Karbowski and Youle 2003). The pro-fission protein, dynamin-related 
protein 1 (Drp1) is recruited to mitochondria where it interacts with a mitochondrial 
receptor, mitochondrial fission 1 protein (Hfis1), to cut mitochondria into smaller units. 
When this happens mitochondria depolarize and usually recover; but if restoration of 
membrane potential fails then the mitochondria may be targeted for degradation by 
autophagy or otherwise apoptosis is induced through cleavage of OPA-1 (Boland, 
2013). 
Mitochondrial dysfunction can occur as a result of perturbations in the balance of 
mitochondrial fission and fusion dynamics, which have been demonstrated in a 
preclinical model of cancer cachexia (Marzetti et al. 2017). In a multifaceted study by 
Xi et al. (2016), mitofusin-2 (Mfn2), was assessed in vitro in the C2C12 cell line, in an 
in vivo mouse model as well as in rectus abdominis muscle tissue from patients who 
underwent primary surgical resection of gastrointestinal cancer. The in vitro model 
indicated that Mfn2 loss was strongly associated with atrophy of C2C12 myotubes, 
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while cachexia decreased both gastrocnemius muscle mass and Mfn2 expression in 
vivo. By overexpressing Mfn2, a partial attenuation of cachexia-induced 
gastrocnemius muscle loss was observed.  Furthermore, Mfn2 protein expression was 
found to be downregulated in muscle biopsies of cachectic patients. These results 
suggest that Mfn2 protects against cachexia-induced muscle loss, and that it may be 
a novel target for the treatment of cachexia in cancer patients. 
Mitophagy is a highly selective form of autophagy where mitochondria are targeted for 
degradation, which may then also serve as a source of nutrients for the cell (Carson 
et al. 2016). Indeed, generalised autophagy may not result in decreased mitochondrial 
content as demonstrated by loss-of-function Atg7 (functions in the autophagy 
pathway) knockout mouse models, where defective mitochondria have been shown to 
accumulate in certain tissue, including skeletal muscle (Komatsu et al, 2005; Wu et al, 
2009). Mitophagy is usually induced to degrade defective mitochondria following 
damage or stress (Lemasters, 2005).  During the mitophagy quality control process, 
the protein, PINK1, identifies damaged mitochondria for hydrolytic degradation. PINK1 
then accumulates and becomes activated on the outer mitochondrial membrane and 
next phosphorylates the polyubiquitin chain and Parkin. This results in the 
translocation and ubiquitination of substrates on the outer mitochondrial membrane. 
Once the outer mitochondrial membrane is tagged by Parkin, the ubiquitinated 
mitochondria undergoes autophagic degradation (Fig. 2.3). Parkin thus mediates 
autophagy downstream of PINK1 (Jin et al, 2012), that selectively binds to defective 
mitochondria. Parkin overexpression had been shown previously to induce mitophagy 
of damaged mitochondria after membrane potential is lost (Narendra et al, 2008).   
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Figure 2.3: PINK1-Parkin-mediated mitophagy. Image modified from Arano and Imai, (2015). 
Mitophagy has been shown to be dysregulated in cancer cachexia (Carson et al. 
2016). Either a decrease or an increase in the associated processes compared to 
homeostatic conditions may contribute to the cachectic state. Mitophagic failure can 
result in an accumulation of impaired mitochondria which can adversely affect 
metabolism and thus muscle mass, whereas hyperactivation of these processes can 
also contribute to skeletal muscle mitochondrial dysfunction (Martinez-Outschoorn et 
al. 2010, Aversa et al. 2016). Recently, it has been shown that mitophagy is induced 
by tumour-related factors in skeletal muscle through IL-6-dependent signalling 
(Pettersen et al. 2017) and further evidence also suggests that IL-6, derived from the 
tumour, is important in regulating mitophagy (VanderVeen et al. 2017). Indeed, 
targeting mitochondrial dysfunction may be a promising area of research to develop 
therapeutic interventions to prevent or limit muscle wasting and energy inefficiency.  
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2.2.3 Calpains system 
Ca2+-dependent proteases, namely the ubiquitously expressed calpains, calpain-1 
and calpain-2 and the non-ubiquitously expressed calpain-3 which is specific to 
skeletal muscle fibres, are responsible for the breakdown of myofibrillar proteins (Stolc 
1977, Murphy 2010). Defective calpain-3 is associated with limb girdle muscular 
dystrophy type 2A (Murphy 2010). Calpains have also been implicated in the 
degradation of other sarcomeric and cytoskeletal proteins in vitro (Purintrapiban et al. 
2003), where it was demonstrated that inhibition of calpain caused a 20% reduction in 
protein degradation. This was also confirmed in a murine hindlimb suspension model 
where sarcomere structure was preserved with calpain inhibition (Salazar et al. 2010). 
These proteases seem to be the initial trigger for skeletal muscle degradation (Cagan 
et al. 1991, Huang and Forsberg 1998), as observed by Smith et al. (2011) who 
demonstrated a 70% increase in calpain activity in gastric cancer patients with minimal 
weight-loss compared to controls, providing evidence for a role of calpains as an initial 
trigger, or at least early activity, in the progression of cachexia prior to the appearance 
of significant clinical changes.  
Despite extensive research in identifying potential substrates of calpain-3, its 
physiological and pathophysiological functions remain poorly defined.  Interestingly, 
since a defect in calpain-3 expression results in limb-girdle muscular dystrophy type 
2A (LGMD2A), where affected individuals experience progressive weakness and 
atrophied trunk muscle (Gallardo et al. 2011), calpain-3 has been suggested to be 
involved in sarcomeric remodelling and maintenance of muscle integrity rather than its 
assumed role in muscle degradation (Beckmann and Spencer 2008). However, 
calpain-3 is thought to have many more functions since it has been observed in the 
sarcolemma (Taveau et al. 2003), the nucleus (Marcilhac et al. 2006, Murphy et al. 
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2011) and in triad-associated protein complexes (Kramerova et al. 2008) other than 
only the sarcomeric cellular compartment alone (Stuelsatz et al. 2010). Calpains may 
play a critical role in initiating the breakdown of myofibrillar protein, via the release 
from their tertiary structures of proteins such as desmin, filamen, tropomyosin, troponin 
T and troponin I; which become suitable for further degradation by proteasomes. 
Calpains do not work only in concert with the proteasome system, since some 
evidence supports a role for co-ordination with caspases in muscle wasting (Mellgren 
et al. 2009). Experimental evidence was provided by Nelson et al. (2012) that calpain 
can promote caspase-3 activation and active caspase-3 can enhance calpain activity 
in diaphragm muscle during protracted mechanical ventilation. 
2.2.4 Caspases and apoptosis 
Activation of the caspases, a set of cysteine proteases, results in cell morphological 
features such as cytoplasmic contraction, chromatin condensation, plasma membrane 
blebbing, and DNA fragmentation which are all characteristics of the apoptotic 
pathway (Sainz et al. 2003). Two major apoptotic pathways of programmed cell death 
include the intrinsic/mitochondrial and extrinsic/death receptor pathways (Lowe et al. 
2004). These pathways intersect at a common juncture encompassing effector 
caspase activation in the execution pathway of apoptosis (Elmore 2007). 
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Figure 2.4: Apoptosis: the two major apoptotic pathways leading to caspase activation. Image acquired from 
MacFarlane and Williams (2004).  
The extrinsic apoptotic pathway  
The death receptor pathway is activated by TNF-α and other cytokines of the same 
gene superfamily via TNFR-associated death domain (TRADD), FAS-associated 
death domain (FADD) and caspase 8 (Marsters et al. 1996). In short, apoptotic cell 
death is promoted by the binding of death ligands to death receptors on the cellular 
surface which signals the cleavage of the N-terminal of the prodomain of caspase-8 
which activates it (Sainz et al. 2003).  After caspase-8 activation a signal is sent to the 
mitochondria to release cytochrome-c from the inner mitochondrial membrane thereby 
promoting the formation of the apoptosome via the addition of pro-caspase 9 and Apaf-
1. This cascade culminates in the cleavage of caspase 3, also causing its activation, 
and subsequent apoptotic cell death. Importantly, cytochrome c release is prevented 
Stellenbosch University  https://scholar.sun.ac.za
21 | P a g e  
 
by Bcl-2 proteins (defined below) and inhibitors of apoptosis protein (IAP) which 
control the release of cytochrome c from the inner mitochondrial membrane (Sainz et 
al. 2003). The extrinsic pathway can also indirectly amplify apoptotic signals by 
triggering the intrinsic pathway (Johnstone et al. 2002). 
The intrinsic apoptotic pathway 
Non-receptor mediated stimuli such as DNA damage, oxidative stress and 
chemotherapeutic drugs that result in mitochondrial stress and mitochondrial 
membrane perturbation trigger the intrinsic apoptotic pathway (Lopez and Tait 2015). 
This mechanism is in contrast to the extrinsic mediated pathway which requires ligand 
binding. The resultant mitochondrial membrane perturbations trigger the release of 
pro-apoptotic proteins, namely cytochrome c and Apaf-1 that activate caspase-9 and 
further downstream caspase-3, which results in the cleavage and degradation of 
cytoplasmic structural proteins and chromosomal condensation (Saelens et al. 2004, 
Putcha et al. 2002, Benn and Woolf 2004). The B-cell lymphoma protein 2 (Bcl2) family 
of proteins exerts regulatory control over the intrinsic pathway by opposing its actions 
(Koff et al. 2015). This family of proteins may act by inhibiting pro-apoptotic proteins 
such as BAX and in so doing prevent cytochrome c release from the mitochondria 
(Wei et al. 2001).   
Caspases are said to be the central executioners of the apoptotic pathway, which act 
by selective cleaving of specific sets of target proteins leading to the loss of biological 
activity of that protein (Jin and El-Deiry 2005). A role for caspases in muscle protein 
degradation was suggested due to the observations of reduced myonuclei numbers 
during muscle atrophy observed in heart failure and Duchenne muscular dystrophy 
(Adams et al. 2001, Sandri 2002). Skeletal muscle apoptosis has also been observed 
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to be increased in motor neuron disorders, denervation, spinal cord injury, muscular 
dystrophy, and atrophy due to hind limb suspension or immobilization as measured by 
transferase end-labelling (TUNEL) or by DNA fragmentation in gel electrophoresis 
(Allen et al. 1997, Tews et al. 1997, Podhorska-Okolow et al. 1998, Adams et al. 1999, 
Borisov and Carlson 2000, Smith et al. 2000, Dupont-Versteegden 2005). A study by 
Siu and Alway (2006) demonstrated that apoptosis inhibition, to a certain degree, 
attenuated muscle atrophy induced by denervation in a Bax knockout mouse model. 
Caspase-3 has also been shown to be involved with actomyosin complex cleavage, 
while caspase-3 inhibition prevented actin fragment accumulation in skeletal muscle 
of diabetic and uremic rats; indicating that activation of caspase-3 may play an early 
role in muscle protein degradation (Du et al. 2004). Other authors disagree with these 
findings on the premise that non-apoptotic cells are unlikely to activate sufficient 
caspase-3 to contribute towards myofibrillar protein turnover (Goll et al. 2008).  There 
is evidence of apoptosis in skeletal muscle in the Lewis lung carcinoma mouse and 
AH-130 hepatoma animal models of cachexia (van Royen et al. 2000), but a role in 
human cancer cachexia has not been proven. In gastric cancer patients with moderate 
weight-loss (mean 6%) similar apoptotic myonuclei numbers compared to controls 
were apparent, accompanied by no increase in caspases (Bossola et al. 2006). 
Current studies are contradictory; it is thus important to remember that skeletal muscle 
fibres are multinucleated and apoptosis of a single nucleus will not result in the death 
of a muscle fibre (Fanzani et al. 2012). Moreover, the transferase end-labelling 
(TUNEL) technique used to detect DNA fragmentation is not specific and may result 
in false positive reactions contributing to difficulties in interpretation of cell death data 
gained from atrophied muscle (Fanzani et al. 2012). 
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2.2.5 Forkhead box O (FoxO) transcription factors 
FoxO3 is the main inducer of autophagy genes such as LC3 and Bnip3 in skeletal 
muscle (Mammucari et al. 2007). Well-coordinated FoxO3-induced gene expression 
is crucial to balanced autophagy. Mammucari et al. (2007) suggested that the 
transcription factor FoxO3 controls both the ubiquitin-proteasome and 
lysosomal/autophagy pathway in muscle but through different mechanisms. This is 
interesting, since it is suggested in several studies that the pathways may not run 
succinctly, as one pathway may be activated and the other remains at basal levels 
(Zhao et al. 2007). FoxO3 is inactive in its phosphorylated form induced by Akt, where 
it resides in the cytoplasm (Brunet et al. 1999); upon dephosphorylation, FoxO3 
becomes active and translocates to the nucleus (Ramaswamy et al. 2002, Sandri et 
al. 2004). Activation of FoxO3 is implicated in muscle atrophy (Sandri et al. 2006) and 
has been shown to activate the E3 ligases MAFBx and MuRF1 (Sandri et al. 2004, 
Stitt et al. 2004). Zhao et al. (2008)  showed that by overexpressing FoxO3 both UPP 
and autophagy mediated proteolysis were increased. This result suggested that under 
UPP control, FoxO3 degraded myofibrillar protein and autophagy was responsible for 
mitochondrial loss. Furthermore, Judge et al. (2014) showed that inhibition of FoxO-
dependent transcription in tumour bearing mice prevented both diaphragm and 
locomotor muscle atrophy and also spared force deficits.  
In humans, decreased phosphorylation of FoxO3a has been observed in the rectus 
abdominis muscle of cachectic compared with non-cachectic pancreatic cancer 
patients (Schmitt et al. 2007). Similarly, FoxO3 was activated in vastus lateralis muscle 
of lung cancer and COPD patients (Puig-Vilanova et al. 2015). 
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2.2.6 Proteolysis-inducing factor (PIF) 
Another catabolic cachectic mediator, proteolysis-inducing factor (PIF), which is 
released from tumours, has been shown to activate the transcription factor, NF-κB 
(Whitehouse and Tisdale 2003). Intravenous administration of PIF degraded 
gastrocnemius muscle in mice and increased mRNA levels for ubiquitin (Lorite et al. 
2001), providing evidence of a mechanism via which PIF functions. Whitehouse and 
Tisdale (2003) later provided evidence that PIF-induced upregulation of proteasome 
expression in C2C12 myotubes may be mediated via NF-κB. NF-κB is known to have 
oncogenic functions and may also mediate muscle protein breakdown by degradation 
of specific muscle proteins, inducing inflammation and fibrosis and halting 
regeneration of myofibres following injury or atrophy (Li et al. 2008).  
2.3 Inhibition of muscle regeneration 
The imbalance between muscle protein synthesis and degradation is known to 
contribute to muscle wasting, with a growing amount of literature now suggesting that 
satellite cell regulation and subsequent regeneration may be impaired in atrophied 
muscle. This notion stems from various studies reporting a decline in the number of 
precursor cells (satellite cells) in atrophied muscle (Guo, 2012, Mitchell, 2004, 
Mozdziak, 2001). Evidence for satellite cell number decline was provided in a study 
which demonstrated that regeneration from acute cardiotoxin injury was blocked 
following prior hind-limb suspension and the impaired muscle mass gain lasted for six 
weeks (Matsuba, 2009). It is yet unclear whether impaired regulation of regeneration 
contributes to muscle atrophy or whether it is a consequence of muscle atrophy. 
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2.3.1 Activation of adult muscle satellite cells, a key element in the regulation of muscle 
regeneration 
Satellite cells (SCs), are precursors to skeletal muscle cells and are under normal 
physiological conditions quiescent and situated in their anatomical position under the 
basal lamina of myofibres (Bischoff 1997, Grounds 2002). These cells are responsible 
for the replacement and reparation of damaged myofibres. Induction of stressors such 
as muscle fibre damage from sarcolemmal wear and tear, acute injuries requiring new 
fibres to be formed or even hypertrophy, activate SCs. These cells then enter the cell 
cycle and begin to proliferate under the guidance of cell cycle regulators and then 
differentiate under the guidance of the myogenic regulatory factors. During 
proliferation satellite cells express both Pax7 and MyoD and can either self-renew and 
thus expand the satellite cell pool or exit the cell cycle (Cornelison and Wold 1997, 
Scime and Rudnicki 2006). Cells exiting the cell cycle produce muscle precursor cells, 
known as myoblasts which now express higher levels of MyoD and also myogenin 
(Fig. 2.5). Next, the newly formed myoblasts fuse to form myotubes, which express 
myogenin and MRF4 and which terminally differentiate into muscle fibres (Tidball et 
al. 2014).  
 
Figure 2.5: Regeneration and muscle growth following injury. Image modified from Tidball et al, (2014). 
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2.3.2 Impaired remodelling in cancer cachexia 
The interaction between the SC and its microenvironment, as well as the interaction 
between the immune system and skeletal muscle are regarded as important role 
players in the regulatory process, both modulating events during repair and 
remodelling. 
Basal lamina disruption and membrane damage result in satellite cells’ activation. In 
two separate studies using C-26 tumour bearing mouse models of cancer cachexia, 
skeletal muscle membrane damage was demonstrated. The more recent study 
showed that the hindlimbs of these mice contained a pronounced accumulation of 
immunoglobulins (IgG) not normally present in muscle fibres, together with diffuse 
laminin staining, increased penetration of Evans blue dye, and reduced expression of 
extracellular matrix genes (He et al. 2013). In the other study, it was demonstrated 
that the myofibres of tumour bearing mice had altered sarcolemmas and basal laminas 
(Acharyya et al. 2005). These data demonstrate sarcolemma and basal lamina 
perturbations in cachectic muscle, most probably due to tumour related factors in 
circulation. 
He et al. (2013), provided the first clear evidence of impaired regeneration in an in vivo 
model of cancer cachexia. The authors provided evidence that Pax7 is abnormally 
elevated in cachectic SCs. To prove this was actually part of the mechanism for 
atrophy, the authors also showed that overexpression of Pax7 (an essential regulator 
of satellite cell expansion and differentiation during embryonic and fetal myogenesis) 
induced atrophy in normal muscle. Moreover, they showed that with reduction of Pax7 
or exogenous addition of MyoD, during tumour conditions, wasting could be reversed 
due to restoration of SC differentiation and fusion. They also demonstrated that Pax7 
dysregulation was induced by circulating pro-cachectic serum factors from cachectic 
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mice and patients, in a NF-κB–dependent manner. Damrauer et al. (2008) reported 
that chemotherapeutic agents such as cisplatin, and doxorubicin may directly cause 
muscle wasting via activation of the NF-κB pathway, and suggested that these effects 
were independent of their inhibition of tumour growth. 
2.4 Doxorubicin 
2.4.1 Structure, function and mechanism of action in tumours 
The chemotherapeutic antibiotic, doxorubicin, was first isolated from mutant 
Streptomyces peucetiusis (Arcamone et al. 1969) in the 1960s and found to be highly 
effective against various solid tumours (Mohammad et al. 2015). The stereochemistry 
and absolute configuration of doxorubicin have been identified by X-ray 
crystallographic analysis (Di Marco et al. 1969) which provided detail on the 
conformation of the molecule in the solid state. This glycoside antibiotic is 
characterized by a planar four-ring quinone-containing chromophore, which has a high 
binding affinity for DNA bearing one, two or three sugar moieties attached at the 7-
position. It is considered one of the most effective agents in the fight against cancer; 
however, its clinical value is compromised by toxicity to both the heart and skeletal 
muscle.  
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Figure 2.6: Chemical structure of doxorubicin in complex with DNA. Image modified from Di Marco et al. (1969). 
Due to its systemic administration and thus non-specific mode of action, doxorubicin 
elicits significant side effects by targeting healthy cells. Doxorubicin induces its 
cytotoxic action through: (i) Topoisomerase II inhibition, (ii) Interference with cell 
respiration and electron transport resulting in oxidative stress, (iii) disruption of cellular 
membrane phospholipids.  
i) Topoisomerase II inhibition 
Topoisomerases are ubiquitous enzymes that exercise regulation over DNA 
replication, transcription and other nuclear processes (Bakshi et al. 2001, Cuvier and 
Hirano 2003). These enzymes act to manipulate the topology of DNA function at 
various steps of replication in both pro and eukaryotes by cutting and re-joining single 
and double stranded DNA, thereby either catalysing addition or removal of supercoils 
to rapidly make DNA accessible for interaction with proteins, which regulate different 
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functions of chromatin (Cuvier and Hirano 2003). Previous studies have demonstrated 
that doxorubicin functions as a topoisomerase II inhibitor (Heart et al. 2016). The 
inhibition of topoisomerase II by doxorubicin prevents cell division, which results in 
programmed cell death via apoptosis or necrosis (Minotti et al. 2004).  
ii) Interference with cell respiration and electron transport resulting in oxidative stress 
Oxidative stress is considered one of the major mechanisms of doxorubicin’s 
antitumour action. Doxorubicin is prone to the generation of oxygen free radicals, since 
it possesses a quinone-hydroquinone group within its structure. Once this quinone 
structure is oxidized, an unstable semiquinone radical is formed which rapidly reacts 
with oxygen to generate free radicals such as superoxide and hydrogen peroxide 
which damages DNA (Yang et al. 2014). Semiquinone radical formation can increase 
aglycone lipid solubility within its structure by further oxidizing the glycosidic bond 
between daunosamine and the aglyconic subunit, allowing for its intercalation into 
biological membranes as well as the production of ROS. Furthermore, iron overload 
may develop in doxorubicin treated cancer patients (Lipshultz et al. 2013) due to blood 
transfusions, blood loss or iron supplementation resulting in doxorubicin-iron complex 
formation which catalyses the conversion of hydrogen peroxide to highly reactive 
hydroxyl radicals (Yang et al. 2014). These free radicals increase oxidative stress 
within tumours, leading to DNA damage and cell death (Yang et al. 2014).  
iii)  Disruption of cellular membrane phospholipids 
Doxorubicin has been shown to bind to phospholipids such as cardiolipin within the 
heart mitochondrial membrane (Goormaghtigh et al. 1990, Kavazis et al. 2017); this 
binding has been suggested as a possible explanation of selectivity of action within 
this class of drugs (Lown et al. 1983). Further evidence for the alteration of cell surface 
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architecture by doxorubicin is described in other studies (Arancia et al. 1995, Suwalsky 
et al. 1999) as well, where it was shown that doxorubicin perturbed the polar head and 
acyl chain regions of lipids and was able to fluidize their hydrophobic moieties. The 
aforementioned studies used a variety of methods to prove doxorubicin’s interaction 
with erythrocyte membranes. It was found to be incorporated into either the inner or 
outer leaflets of the erythrocyte membrane (Suwalsky et al. 1999) causing 
modifications of the cell morphology and membrane ultrastructure (Arancia et al. 
1995), which might induce anaemia, in cancer patients. Furthermore, it was also 
demonstrated that doxorubicin is incorporated into the membranes of skeletal muscle 
(Peters et al. 1981, Hayward et al. 2013), where current research indicates that long 
term effects may persist in skeletal muscle for many years following chemotherapy 
treatment (Fabris and MacLean 2015), independent of cancer cachexia. 
2.5 Doxorubicin-induced mechanisms of muscle protein degradation 
It is well documented that doxorubicin treatment causes skeletal muscle atrophy as 
well as loss of function, However, mechanisms of doxorubicin-induced skeletal muscle 
atrophy are not well characterised, although it has been proposed that the induction 
of oxidative stress constitutes a common denominator. Since doxorubicin strongly 
binds the membranes of mitochondria which are specifically dense in skeletal muscle, 
it seems plausible that myotoxicity is mediated via doxorubicin-induced mitochondrial 
ROS mediated dysfunction, especially since symptoms of myotoxicity include fatigue, 
weakness and exercise intolerance. As previously described, doxorubicin’s unique 
chemical structure contains an unsubstituted quinone that is able to form a redox cycle 
with electron donors thereby promoting superoxide radical production at complex I of 
the electron transport chain (Minotti et al. 2004), thus removing electrons needed for 
ATP production. Since one of doxorubicin’s primary functions is to fragment DNA, 
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poly-ADP-ribose polymerases (PARPs) will be activated in order to repair damaged 
DNA at a metabolic cost. PARPs require energy cofactors such as NAD+ for repair to 
DNA, thus consuming ATP, adding to energy imbalances. Interestingly, this leads to 
reduced SIRT-1 activity - a protein that provides protection against chronic 
inflammation, induces mitochondrial biogenesis  and increases skeletal muscle 
oxidative capacity (Bai et al. 2011). Gilliam et al. (2012) demonstrated that ROS levels 
were increased following exposure of C2C12 cells in culture to doxorubicin. The 
elevation in ROS was followed by an upregulation of E3 ubiquitin ligases and caspase-
3. Furthermore, when an antioxidant was added, mitochondrial ROS formation was 
inhibited. Moreover, it has been shown that ROS can contribute to the activation of 
calpain by acting as a signalling molecule (Storr et al. 2011). ROS is also largely 
implicated in the activation of caspase-3 and subsequent apoptosis, thereby promoting 
atrophy (Storr et al. 2011, Tsai et al. 2010, Smuder et al. 2011). These muscle 
degradative systems may then catalyse the release of myofilament proteins, allowing 
activation of the ubiquitin-protease system (Powers et al. 2005, Du et al, 2004, Smuder 
et al. 2011).  
In a recent study by Gilliam et al. (2016) it was demonstrated that the overexpression 
of catalase in mitochondria of muscle diminished mitochondrial H2O2 emission and 
protein oxidation, preserving mitochondrial and whole muscle function despite 
doxorubicin treatment in an in vivo cancer model. Gouspillou et al. (2015) studied 
doxorubicin & dexamethasone-induced long-term mitochondrial respiration 
impairment in skeletal muscle in non-tumour bearing mice. The authors showed that 
treated animals had lower muscle mass and impaired growth as well as an attenuation 
in mitochondrial respiration and increased ROS production. They further observed 
reduced protein levels of Parkin which suggested a novel pattern of chemotherapy-
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induced mitochondrial dysfunction in skeletal muscle that persists due to an acquired 
defect in mitophagy signalling.  
It is postulated that the generation of mitochondrial ROS by doxorubicin could lead to 
activation of proteolytic and catabolic pathways. This was demonstrated by Kavazis et 
al. (2014), who showed that doxorubicin administration increased FoxO1 and FoxO3 
mRNA expression in skeletal muscle. The transcription of FoxO targeted genes 
namely, MaFbx, MuRF-1, and BNIP3 were also found to be elevated in both heart and 
soleus muscles. Exercise training prevented these doxorubicin-induced elevations by 
increasing PGC-1α, which is a known suppressor of FoxO activity. Smuder et al. 
(2011) first showed that markers of autophagy (mRNA and protein) were increased 
following doxorubicin administration in rat soleus muscle and also found that 
prophylactic endurance exercise protected skeletal muscle against DOX-induced 
activation of autophagy. Doxorubicin may also indirectly promote muscle degradation 
via systemic mechanisms.   
2.5.1 Doxorubicin-induced anaemia and leukopenia and iron-binding in muscle 
tissue 
 
Doxorubicin targets and destroys rapidly dividing cells, which are characteristic of 
cancer. However, many other rapidly dividing normal cell types are destroyed in the 
process which include bone marrow and by extension, blood cells, a condition known 
as myelosuppression (Bhinge et al. 2012). Doxorubicin interacts with free iron in red 
blood cells forming a doxorubicin-iron complex which self reduces, resulting in the 
generation of potent free radicals causing lipid peroxidation and DNA damage 
(Vaidyanathan and Boroujerdi 2000). Shinohara and Tanaka (1980) reported that 
doxorubicin peroxidises human red blood cell membrane lipids as well as thiols which 
result in glutathione instability and the oxidation of haemoglobin and membrane 
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protein components. Doxorubicin treatment is also strongly associated with aplastic 
anaemia, leukopenia and thrombocytopenia (Nurgalieva et al. 2011). Furthermore, 
doxorubicin-induced leukopenia (Henry et al. 1993) considerably weakens the 
immune system and is associated with poor prognosis in cancer patients (Bhinge et 
al. 2012). 
The iron binding properties of doxorubicin extend beyond blood cells to other tissue 
including cardiac and skeletal muscle (Octavia et al. 2012). Miranda et al. (2003)  
showed that HFE (an iron regulatory gene) deficient mice were more susceptible to 
doxorubicin-induced cardiotoxicity. It is however argued that not enough free iron is 
present within most cells for doxorubicin to couple with under physiological conditions, 
therefore doxorubicin-iron coupling may not always result in myopathy (Minotti et al. 
2004). However, Minotti et al. (1998) provided evidence that the major metabolite of 
doxorubicin, doxorubicinol forms complexes with iron regulatory proteins, thus 
stabilizing transferrin mRNA resulting in the prevention of iron sequestration and 
protein translation. This leads to increased free iron, which could propagate the cycle 
of free radical generation. Panjrath et al. (2007) found that cardiotoxicity was 
enhanced in an iron loading rat model, further supporting the role of iron in the 
pathogenesis of doxorubicin-induced cardiotoxicity. 
It is thought that iron-containing protein complexes which are plentiful in muscle 
tissues are one of doxorubicin’s preferred accumulation sites in skeletal muscle 
(Octavia et al. 2012). Indeed, muscle iron dyshomeostasis has been linked to 
pathogenesis of both sarcopenia of aging and disuse-induced muscle atrophy (Xu et 
al. 2010). Furthermore, in a model of disuse atrophy in aged rodents significantly 
increased iron levels in skeletal muscle have been associated with widespread 
oxidative damage (Hofer et al. 2008). Gilliam et al. (2013) speculated that potential 
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sources of doxorubicin-induced oxidants within skeletal muscle are from redox cycling 
within mitochondria, and the inactivation of the electron transport system. The authors 
further speculated that hydroxyl radicals are formed from H2O2 leading to lipid 
peroxidation in the presence of redox active iron, thus altering mitochondrial and 
myofilament proteins (Gilliam et al. 2013).     
2.5.2 Doxorubicin and satellite cells 
Little is known about the effects of doxorubicin on satellite cell function. In an in vitro 
study to determine if the overexpression of antioxidants protects against doxorubicin-
induced cell death in primary satellite cell cultures derived from the hindlimb muscles 
of mice, the investigators found that overexpression of the cytosolic antioxidant 
enzyme, CuZnSOD, protects against DNA fragmentation, and enhanced cell survival. 
The overexpression of the mitochondrial enzyme, MnSOD, also enhanced cell survival 
in response to an apoptosis-inducing dose of doxorubicin (Soltow et al. 2007). 
As mentioned earlier in the introduction, doxorubicin is used clinically to permanently 
remove muscle from the eyelids of patients to treat blepharospasm (Wirtschafter and 
Mcloon 1998). Nguyen et al. (1998) further demonstrated that doxorubicin 
chemomyectomy was more effective when introduced two days post muscle injury 
since this coincided with peak satellite cell division, demonstrating doxorubicin’s effect 
is most potent during mitosis.   
Survivors of childhood cancers, such as acute lymphoblastic leukaemia, have 
increased rates of long-term skeletal muscle dysfunction due to treatment with 
doxorubicin and other anthracyclines (Gouspillou et al. 2015). During cytotoxic 
conditions such as oxidative stress, activated satellite cells seem to be more 
susceptible to oxidative stress damage than quiescent satellite cells (Pallafacchina et 
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al. 2010). The average age of these cancer patients when seeking treatment is 4 years 
which corresponds with the period in life when satellite cells are still highly active and 
proliferating due to skeletal muscle growth. Thus, exposure of activated muscle 
satellite cells to chemotherapy-induced oxidative stress during this time, may impair 
satellite cell function and the ability to adequately replenish the quiescent cell 
population (Chen et al. 2007). This lead Scheede-Bergdal and Jagoe (2013) to infer 
that chemotherapy-induced early depletion of muscle satellite cells may be one 
mechanism for chemotherapy-related muscle dysfunction. 
2.6 Managing cancer and cachexia 
2.6.1 Current treatment strategies for cancer cachexia 
Current treatments targeting cancer cachexia appear to be limited or have not shown 
the desired results. This is proposedly due to the complex nature of cancer cachexia, 
which involves an array of factors such as metabolic abnormalities, pro-inflammatory 
cytokines, tumour-derived catabolic factors and decreased food intake ( Macciò et al. 
2012, Mantovani et al. 2001).  Various treatment strategies have been suggested to 
target muscle wasting, from multimodal pharmacological to nutritional and antioxidant 
approaches, with some treatments showing significant increases in skeletal muscle 
strength and size in clinical trials (Greig et al. 2014), and improvements in appetite, 
body weight, and caloric intake (Gagnon and Bruera 1998, Mantovani et al. 2001, 
Mantovani and Madeddu 2008). Corticosteroids have also shown some promise, with 
results from clinical studies reporting increased appetite, improved pain control, and 
improved perceived quality of life in patients suffering from cancer cachexia (Gagnon 
and Bruera 1998; Mantovani et al. 2001). Other strategies under investigation are 
either to enhance chemotherapeutic drug delivery via PEGylated liposomes (Cohen 
et al. 2018, Ma and Mumper 2013) or to administer agents which target the 
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proteasome system. Some proteasome inhibitors successfully attenuate atrophy in 
various animal models (Supinski et al. 2009, Caron et al. 2011, Jamart et al. 2011, 
Bonaldo and Sandri 2013); however this was ineffective in human clinical trials (Jatoi 
et al. 2005). 
Another category of drug treatments are those which target ROS and cytokine release, 
such as melatonin (Leja-Szpak et al. 2018, Mantovani et al. 2001), eicosapentaenoic 
acid (EPA) (Jatoi et al. 2004), nonsteroidal anti-inflammatory drugs, or those 
antagonizing muscle wasting, such as clenbuterol and anabolic agents, growth 
hormone and insulin-like growth factor (Kim et al. 2011, Mantovani et al. 2001).  
Due to the aberrant nature of cancer cachexia, it is proving quite difficult to completely 
stunt excessive muscle wasting. Below the potential for targeting reactive oxygen 
species in attenuating muscle wasting associated with cancer, with particular 
emphasis on the contribution of antioxidants, will be discussed. 
2.6.2 Antioxidants 
Positive results for antioxidant treatment in muscle disease models have been 
reported in a number of studies.  Alpha linoleic acid (ALA) an n−3 fatty acid with 
antioxidant activities, has been shown to induce protein synthesis in C2C12 myotubes 
via the PI3K/Akt signalling pathway thereby modulating skeletal muscle turnover (Jing 
et al. 2016). Furthermore, antioxidant-supplementation (resveratrol) improved weight 
gain in tumour-bearing mice (Shadfar et al. 2011). However, in two separate in vivo 
C26 adenocarcinoma-induced mouse cachexia models, it was found that the selected 
antioxidants failed to attenuate muscle loss (Tian et al. 2011, Assi et al. 2016). In the 
first study by Tian et al. (2011) it was demonstrated that conjugated linoleic acid, which 
is thought to have anti-cancer and antioxidant properties, failed to attenuate muscle 
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wasting and furthermore it was found that the supplement increased expression of 
inflammatory markers in muscle. In the more recent study by Assi et al. (2016), an 
antioxidant cocktail, comprised of catechins (polyphenol), quercetin and vitamin C, 
failed to attenuate muscle loss in the C26 tumour-bearing mouse model, but instead 
the cocktail combination resulted in cachexia enhancement and reduced survival.  The 
successful and the unsuccessful studies used the same C26 adenocarcinoma tumour 
bearing mouse model and tumours were allowed to grow for 17 days. Tumour weight 
in the study by Tian et al. (2011) weighed approximately double in mass compared to 
the successful study by Shadfar et al. (2011), as 250 000 more C26 adenocarcinoma 
cells were inoculated on study day 0. 
In humans, Persson et al. (2005) investigated the effects of fish oil, melatonin or a 
combination of the supplements in cachectic patients with advanced gastrointestinal 
cancer. They found that the supplements did not induce major biochemical changes 
in the muscle of patients, but they did observe a weight-stabilizing effect. In a different 
clinical trial, treatment with antioxidants (alpha-lipoic acid + carbocysteine lysine salt 
+ vitamin E + vitamin A + vitamin C), drugs (medroxyprogesterone acetate and 
selective cyclooxygenase-2 inhibitor celecoxib) and pharmaco-nutritional support was 
beneficial in a population of advanced cancer patients with anorexia/cachexia. In this 
study increased body weight and appetite, as well as decreased pro-inflammatory 
cytokines and improved fatigue symptom scores were observed (Mantovani et al. 
2006). It is clear from literature that the roles of antioxidants in cancer cachexia are 
not fully elucidated yet. In a recent review by Assi and Rebillard (2016), it was 
concluded that antioxidant therapy may: 1) benefit cancer cachectic patients’ deficient 
in antioxidants; 2) be of harm to cancer patients with sufficient antioxidant status, and 
3) not be recommended whilst undergoing radiotherapy.   
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2.7 Melatonin 
2.7.1 Structure, function, synthesis and secretion  
First isolated in the late 1950’s (Lerner et al. 1959), melatonin (N-acetyl-5-
methoxytryptamine) is a naturally occurring light sensitive multi-tasking hormone 
produced in the brain and primarily secreted by the pineal gland (Tasdemir et al. 2012). 
Numerous other non-pineal tissue also have the ability to synthesize melatonin such 
as the retina, ciliary body, lens, Harderian gland, brain, thymus, airway epithelium, 
bone marrow, gut, ovary, testicles, placenta, lymphocytes and skin (Tan et al. 2007). 
Both its release and synthesis are sensitive to light-dark conditions. Photosensitive 
retinal ganglion cells relay information regarding light-dark exposure to the 
suprachiasmatic nucleus of the hypothalamus, the region of the brain which 
coordinates biological clock signals, thus regulating melatonin’s secretion (Brennan et 
al. 2007). The synthesis of melatonin gradually rises at night and levels are extremely 
low during the day, occurring in a diurnal fashion. This compound’s main function is to 
regulate the central circadian clock and oscillators in peripheral tissue and organs, 
thereby influencing almost all cell processes and other body functions which include 
antioxidant (Tasdemir et al. 2012), anti-inflammatory (Laste et al. 2012), analgesic 
(Laste et al. 2012), immunomodulatory (Srinivasan et al. 2008), thermoregulatory 
(Krauchi et al. 2006) and neuroprotective (Alonso-Alconada et al. 2013) properties. 
Furthermore, melatonin’s potential applications are being explored in areas as diverse 
as cancer (Cutando et al. 2012), ophthalmology (Rosenstein et al. 2010), haematology 
(Li et al. 2017), toxicology (Malhotra et al. 2004), sleep (Bramley et al. 2017), 
cardiology (Zhang et al. 2017), ageing (Bubenik and Konturek 2011), immunity 
(Srinivasan et al. 2008), and osteoporosis (Liu et al. 2013).  
 
Stellenbosch University  https://scholar.sun.ac.za
39 | P a g e  
 
 
Figure 2.7: Biochemical pathway for the synthesis of melatonin from tryptophan (Hickman et al. 1999). 
Serotonin is a precursor of melatonin and is derived from tryptophan. This 
neurotransmitter first undergoes acetylation via a serotonin N-acetyltransferase (NAT) 
(which is considered the rate limiting enzyme in the process) into N-acetylserotonin. 
N-acetylserotonin next undergoes methylation via an enzyme methyltransferase in the 
pineal gland to yield melatonin (see Figure 2.7) (Hickman et al. 1999). Evidence 
contrary to the NAT as rate limiting enzyme paradigm suggests that melatonin 
synthesis in fact may be limited by the speed of conversion from N-acetylserotonin to 
melatonin, which is mediated by methyltransferase (Chattoraj et al. 2009). Once 
synthesised, melatonin is immediately released into circulation where (Chattoraj et al. 
2009) peak levels would range from 54 – 75 pg/mL and 18 – 40 pg/mL for young and 
old individuals respectively. The serum half-life of endogenous melatonin typically 
ranges from 30-60 mins whereas exogenous melatonin levels have a shorter half-life 
of between 12-48 mins.    
Melatonin exerts its effects directly via two main membrane bound receptors namely 
melatonin receptor 1 and melatonin receptor 2 (MT1 and MT2 respectively), both of 
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which are G protein-coupled transmembrane receptors. These receptors are 
ubiquitously expressed throughout the body, including the brain, immune system, 
testes, skin, retina, kidneys and in the breasts. Melatonin has been shown to activate 
several signalling pathways; most notably the Ca2+-dependent pathways, which 
include the cAMP and Phospholipase C pathways. Dubocovich et al. (2003 & 2010) 
argue that melatonin’s biological activity may also be mediated via non-receptor 
mediated antioxidant activity. Moreover, melatonin is highly lipophilic and water 
soluble which means it can readily diffuse across cell membranes and into circulation 
for effective delivery to the CNS and other organs (Nosjean et al. 2001). Melatonin 
further may mediate its actions indirectly via nuclear orphan receptors from the 
RORα/RZR family; this however remains controversial and researchers studying 
nuclear receptors question whether melatonin may be a ligand of the receptor tyrosine 
kinase-like orphan receptors (ROR) (Slominski et al. 2016). Researchers have also 
described a third melatonin receptor (MT3), however this turned out to be a cytosolic 
enzyme quinone reductase 2 (Ferry et al. 2010).  
2.7.2 MT receptors in skeletal muscle  
 
Omnipresent MT receptors also operate within skeletal muscle tissue. Recently, 
Owino, et al. (2016) analysed relative mRNA levels in skeletal muscle of wild type, 
MT1-/- and MT2- /- mice. They found that the daily rhythms in blood glucose levels were 
lost in MT1-/- and MT2- /- mice and interestingly that signalling via the MT receptor 
produced negligible effects on rhythmic expression patterns of clock genes in insulin 
sensitive tissues such as the liver, adipose tissue, and skeletal muscle. More recently 
MT1a mRNA expression was found to be up-regulated in contusion injured skeletal 
muscle of male Wistar rats treated with MLT (Mehanna et al. 2017). Treatment with 
MLT further significantly increased twitch force and decreased Bax levels of injured 
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soleus muscle compared to the injured non-treated group. Histological analysis of MLT 
treated injured soleus muscle revealed less inflammatory cellular infiltration and 
vascular congestion at 1 and 4 days after injury compared to the injured non-treated 
group. The authors concluded that the presence of MT receptors in injured muscle 
may have direct effects in contused muscle, whilst co-ordinating possible systemic 
effects which further indirectly support the restoration of injured muscle (Mehanna et 
al. 2017). This data provides evidence that MLT supports muscle restorative capacity 
in contusion injured muscle. 
2.7.3 Melatonin and Breast Cancer  
The International Agency for Research on Cancer has classified “shift-work that 
involves circadian disruption” as “probably carcinogenic to humans” (Rondanelli et al. 
2013). Melatonin secretion disruption by night-time light exposure has been 
hypothesised to play a role in breast cancer (Jasser et al. 2006, Ravindra et al. 2006, 
Shadan 2007), since melatonin secretion is impaired in breast cancer patients (Lissoni 
2002). Indeed many in vitro (Sainz et al. 2003, Garcia-Santos et al. 2006, Garcia-
Navarro et al. 2007) and in vivo (Srinivasan et al. 2008) studies have confirmed 
melatonin’s oncostatic and antiproliferative effects in different cancer cell types as well 
as in a variety of solid tumours.   
In a study by Bartsch et al. (1981), it was shown that urine melatonin levels in 
postmenopausal women with advanced stage breast cancer was 31% lower compared 
to controls. Furthermore, melatonin excretion patterns in these patients were not 
synchronised as compared to synchronised controls, suggesting both melatonin 
secretion and rhythm are modified in breast cancer patients (Bartsch et al. 1981). In a 
clinical trial by Lissoni et al. (1995), ER-negative metastatic breast cancer patients who 
were unable to continue with chemotherapy were treated with tamoxifen and 
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melatonin. Patients treated with melatonin as adjuvant together with tamoxifen had a 
significantly higher one year survival rate compared to tamoxifen treatment alone. No 
melatonin related toxicity was observed; furthermore, melatonin reduced anxiety and 
depression in these patients. In a recent study by Innominato et al. (2016), where sleep 
quantity and quality of life in patients with advanced breast cancer were evaluated, it 
was found that melatonin treatment improved fatigue and sleep problems in these 
patients. The results of this study were supported by another study which 
demonstrated that melatonin significantly changed sleep efficiency after breast cancer 
surgery (Madsen et al. 2016). Additionally, melatonin has been found to be beneficial 
as adjuvant therapy when used in conjunction with chemotherapeutic agents in 
patients suffering from melanoma and breast cancer (Kilic et al. 2013). Although 
mounting evidence points toward melatonin’s potential as adjuvant therapy for breast 
cancer patients, clinical evidence is still limited. 
2.7.4 Melatonin the unique antioxidant 
The indole moiety of the melatonin molecule is characterised as having high 
resonance stability and a very low activation energy barrier toward oxidative reactions, 
while, the molecule’s methoxy and amide side chains add to melatonin's antioxidant 
capacity, the methoxy group prevents pro-oxidative activity of the molecule (Tan et al. 
2002). Since the early nineties when it became evident that melatonin possesses 
potent radical-scavenging properties, numerous in vitro and in vivo studies have 
further confirmed this (Tesoriere et al. 1999, Tan et al. 2002). For a summary, see 
Table 1. These studies have demonstrated that melatonin scavenges a wide variety 
of radicals, including reactive oxygen (Zang et al. 1998) and nitrogen species (Reiter 
et al. 2001) hydroxyl radicals (Kaneko et al. 2000), hydrogen peroxide (Tan et al. 
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2000), singlet oxygen, nitric oxide and peroxynitrite anions (Cagnoli et al. 1995, Tan 
et al. 2002, Aydogan et al. 2006, Schaefer and Hardeland 2009).  
 
 
Melatonin is capable of functionally supporting several antioxidant enzymes, as well 
as inducing the activity of enzymes responsible for stimulating the production of the 
antioxidant, glutathione (Korkmaz et al. 2008). Moreover, melatonin has been shown 
to be more effective and potent than vitamin E, beta-carotene or vitamin C as 
antioxidants (Gultekin et al. 2001, Montilla et al. 2001, and Lamont et al. 2015). What 
further sets melatonin apart from other antioxidants is that a single melatonin molecule 
is capable of scavenging up to 4x or more reactive species than other antioxidants 
such as vitamin C and E (Tan et al. 2002). Furthermore, all intermediates stemming 
Table 1: Studies where the  anti-oxidant effect of melatonin is demonstrated in vitro and in vivo. 
Study  [Melatonin]  Effect    References 
In vivo  Up to 1mM   iNOS    Leon et al., 1998 
In vivo  10-60mg/kg BW  NO by iNOS   Crespo et al., 1999 
In vivo  10 mg X 2   Lipid peroxidation products  Gitto et al., 2001 
     (MDA & 4-HDA) in septic  
     newborns 
In vivo  10-20 mg/kg   MDA & NO   Taysi et al., 2003 
In vivo  5 or 10 mg   MDA and ischemia-  Şener et al., 2006 
     reperfusion induced markers  
     of tissue damage  
in vivo  3 g/mL water   cadmium-induced lipid Poliandri et al., 2006 
     peroxidation  
In vivo  4 mg/kg   eNOS in alcoholic rats Sönmez et al., 2009 
In vitro  5 mg/kg   paraquat-induced MDA,  Melchiorri et al., 1996 
     4-HAD & mortality 
In vitro  N/A    lipid peroxidation induced  Longoni et al., 1998 
     by linoleic acid 
In vitro  N/A    OH-induced DNA damage  Romero et al., 1999 
In vitro  100-2000 M   hydroperoxide induced Zavodnik et al., 2006 
     lipid peroxidation   
In vitro  100 g    t-BHP induced toxicity, Hibaoui et al., 2009 
     ROS, and apoptosis 
Abbreviations: MDA, malondialdahyde; 4-HAD, 4-hydroxyalkenals; NO, nitric oxide; iNOS, nitric oxide 
synthase; OH, hydroxide; t-BHP, Tert-butylhydroperoxide. 
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from its interaction with reactive species are also free radical scavengers absent of 
pro-oxidative activity, a property which other antioxidants do not possess (Poeggeler 
et al. 2002, Tan et al. 2002). The downstream benefits of these antioxidant properties 
are illustrated below (see Figure 2.8). 
 
Figure 2.8: The antioxidant cascade of melatonin and mechanisms of protection against oxidative damage. In this 
review, melatonin is considered to independently protect the cell as well as via three further mechanisms which 
may be involved in maintaining mitochondrial homeostasis. Adapted from Zhang and Zhang (2014). 
2.7.5 Circulatory effects of melatonin (Anaemia and Leukocytosis) 
It has previously been demonstrated that the pineal gland through melatonin controls 
haematopoiesis of both red and white blood cells (Maestroni 1998, Lissoni et al. 2003), 
confirming the hormone’s immunoregulatory role (Maestroni 1999). This was clearly 
demonstrated in a clinical trial where twenty metastatic lung cancer patients were 
treated with the chemotherapeutic drugs, cisplatin (a treatment notorious for its 
anaemia inducing properties) and etoposide (Lissoni et al. 2003). Patients received 
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either chemotherapy alone or a combination of chemotherapy and 5-
methoxytryptamine (5-MTT is a metabolite of melatonin). It was demonstrated in this 
study that 5-MTT administration reduced cisplatin-induced anaemia and significantly 
increased haemoglobin levels when compared to the group which only received 
chemotherapy (Lissoni et al. 2003). With the aid of an electrochemical technique, 
adsorptive stripping voltammetry, it was found that similar to doxorubicin, melatonin 
also has a binding affinity for iron (Limson et al. 1998, Maharaj et al. 2003). This 
evidence suggests a further role for melatonin in reducing free radical generation. It 
was also discovered that melatonin was actively taken up into oxidatively stressed 
human red blood cells which protected them against haemolysis and attenuated 
modifications to haemoglobin and membrane proteins (Tesoriere et al. 1999). Lissoni 
et al. (1996) investigated the effects of melatonin treatment in patients who suffered 
from thrombocytopenia due to a variety of causes. An oral dosage of 20 mg/day of 
melatonin normalised platelet number in 57% of patients and significantly increased 
average platelet number. The same group later observed that melatonin significantly 
improved thrombocytopenia and leukopenia in patients with untreatable advanced 
solid tumours receiving supportive care (Lissoni 2002). 
Espino et al. (2013) treated human leukocytes with TNF-α and cycloheximide 
(caspase-8 promoter) which induced an increase in apoptotic cell death of leukocytes; 
pre-treatment with melatonin reduced leukocyte apoptotic cell death. The authors 
showed that melatonin binding to its receptors induced an ERK-dependent signalling 
cascade which increased levels of the anti-apoptotic protein, cFLIP (Espino et al. 
2013). 
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Figure 2.9: Proposed mechanism of action of melatonin in counteracting tumour/doxorubicin-induced muscle 
alterations. Diagramme modified from Pin et al. (2015). 
2.7.6 Melatonin and skeletal muscle atrophy 
It is suggested from the evidence in several in vitro studies that melatonin should be 
able to attenuate skeletal muscle atrophy (Park et al. 2013, Favero et al. 2015). A 
recent study by Salucci et al. (2017)  provided evidence that melatonin was able to 
modulate cell death in C2C12 myotubes where pre-treatment of myotubes with 
melatonin, followed by known apoptotic and oxidative stress inducing compounds 
such as, H2O2, etoposide and staurosporine, reduced membrane blebbing, chromatin 
condensation, myonuclei loss and in situ DNA cleavage. Furthermore, melatonin also 
prevented mitochondrial dysfunction. 
A literature search revealed only three in vivo studies where the effects of melatonin 
treatment in the prevention of skeletal muscle atrophy were investigated. In the first 
study, the effect of melatonin treatment (6 mg/kg) on soleus muscle fibre diameter and 
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ultrastructure in a rat castration model was investigated (Oner et al. 2008); melatonin 
treatment was found to increase skeletal muscle fibre diameter and also to preserve 
the muscle ultrastructure of castrated rats. It was concluded that melatonin treatment 
was as effective as testosterone treatment in the prevention of skeletal muscle atrophy 
through the IGF-1 axis. A more recent study conducted on rats treated with melatonin 
(10 mg/kg) using a contusion spinal cord injury model, demonstrated a decrease in m-
RNA expression of atrophy markers, MAFbx and MuRF-1, as well as the down 
regulation of expression of autophagy proteins LC3-II and Beclin-1 with melatonin 
treatment (Park et al. 2012). Furthermore, Lee et al. (2012) demonstrated that long 
term prophylactic treatment of melatonin (8 weeks) was able to attenuate 
gastrocnemius and soleus muscle loss in stroke-induced muscle atrophy in rats. 
Atrophy related genes, MuRF1 and MAFbx, were significantly down-regulated in the 
gastrocnemius muscle whereas only MAFbx mRNA levels were attenuated in the 
soleus muscle, while insulin-like growth factor-1 receptor (IGF-1R) was found to be 
significantly over-expressed in both gastrocnemius and soleus muscle of rats treated 
with melatonin.  
 IGF-1 is a mitogenic factor which regulates muscle satellite cell proliferation and 
differentiation as well as myofibril growth and regeneration. It has also previously been 
proposed that IGF-1 can regulate the central clock in the suprachiasmatic nucleus 
(Zheng and Sehgal 2010). It was observed that daily rhythmic control of IGF-1 levels 
in breast cancer patients differed to that of other growth factors, further supporting this 
proposition (Haus et al. 2001). An in vivo experimental cancer rat model (Costelli et al. 
2006) and a doxorubicin-induced nephrotic syndrome model (Feld and Hirschberg 
1996) also associated disease with lower circulating levels of IGF-1 than controls. 
However, treatment with exogenous IGF-1 did not prevent cancer cachexia in an in 
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vivo experimental model (Costelli et al. 2006). It has also previously been shown in 
vitro that melatonin stimulates glucose transport (Ha et al. 2006) and glucose 
synthesis (Nduhirabandi et al. 2012) by increasing the phosphorylation level of insulin 
receptor substrate-1 (IRS-1) and hence the phosphoinositide 3-kinase (PI-3-kinase) 
pathway. The way in which melatonin stimulates the phosphorylation of IRS-1 remains 
unknown.  
2.7.7 Melatonin and its effects on skeletal muscle protein degradation in response to 
cancer cachexia 
Several pro-inflammatory cytokines derived from tumour cells and activated 
leukocytes including IL-1, IL-6 and TNF-α are cachectic mediators (Reid and Li 2001, 
Tisdale 2008, Fearon et al. 2012). TNF-α in particular has direct catabolic effects on 
skeletal muscle as it increases the ubiquitin proteasome pathway (Reid and Li 2001). 
Results from clinical trials where patients received supportive care or supportive care 
together with 20 mg/kg melatonin treatment daily for 3 months suggest that melatonin 
may decrease circulating TNF-α levels in cancer patients with untreatable metastatic 
solid tumours (Lissoni et al. 1996).  
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Figure 2.10: The effects of cancer-cachexia induced TNF-α expression on protein degradation as well as possible 
beneficial actions of melatonin. Adapted from VanderVeen et al. (2017). 
In a randomized, non-placebo controlled study where 24 patients with advanced 
gastrointestinal cancer with a body weight reduction of at least 10% in a period over 6 
months were either treated with melatonin (18 mg/day), fish oil (30 mL/day), or a 
combination of both (Persson et al. 2005), no significant reduction in plasma 
inflammatory cytokines were observed; however a weight stabilising effect was 
observed in all 3 groups. A major limitation of this study was the exclusion of a control 
group, however, these findings nonetheless implied a potential anticachectic role for 
melatonin in cancer cachexia. In an in vitro study conducted by Park et al. (2013) 
where L6 myotubes were exposed to TNF-α (100 ng/mL), ROS generation was 
induced and a decreased cell viability was observed. The authors demonstrated that 
the treatment with TNF-α compromised L6 myotubes, but if administered with 
melatonin, the addition of melatonin significantly attenuated the TNF-α induced 
reduction in myotube width and  decreased proteolysis, apoptosis and ROS generation 
(Park et al. 2013). Moreover, in an elegant study by Sacco et al. (1998), melatonin’s 
effect on TNF- production both in vitro and in vivo was investigated (Sacco et al. 1998). 
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In vitro results showed that melatonin directly inhibits TNF-α production in human 
peripheral blood mononuclear cells treated with lipopolysaccharide. Furthermore, in 
vivo results showed that TNF-α production was inhibited in adrenalectomised or 
hypophysectomised mice in an endotoxic shock model. The authors concluded that 
the mechanism by which melatonin inhibited the effects of TNF-α is mainly due to its 
anti-oxidant activity and that it does not act via the hypothalamic–pituitary–adrenal axis 
(Sacco et al. 1998).  
2.7.8 Melatonin and its effects on the mitochondria in cancer cachexia 
Cancer cachectic patients often complain of fatigue. It is well known that cytokine 
regulation and oxidative metabolism are disrupted in these patients, which may well 
contribute to reduced metabolic function and muscle mass loss (Suzuki et al. 2013, 
Carson et al. 2016). It has previously been shown that ATP infusion significantly 
inhibited loss of body weight, fat mass and fat-free mass in patients with advanced 
lung cancer (Agteresch et al. 2002). The inability to efficiently produce ATP further 
highlights the dysfunctional muscle oxidative metabolism cancer cachectic patients 
experience (Agteresch et al. 2000, McLean et al. 2014), which may involve 
mitochondrial dynamics, mitophagy, and biogenesis (see Figure 2.11) (VanderVeen 
et al. 2017). Melatonin has previously been shown to regulate ATP production through 
complexes I and IV of the electron transport chain by increasing oxidative 
phosphorylation enzymes in different tissue types (Martin et al. 2002, Paradies et al. 
2015). A recent publication by Ozkok et al. (2016) demonstrated that melatonin 
treatment prevents muscle damage by increasing ATP levels in a rodent model of 
endotoxemic shock.  
Chen et al. (2010) observed fragmented in skeletal muscle mitochondria and 
accumulated mitochondrial DNA mutations in a mitofusin (Mfn1&2) double knockout 
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mouse model. Mitofusin is present in both mitochondria and sarcoplasmic reticulum 
and is required for normal endoplasmic reticulum (Zorzano 2009) and mitochondrial 
morphology (Zorzano 2009, Ainbinder et al. 2015). Ainbinder et al. (2015) investigated 
the role Mfn2 plays in sarcoplasmic reticulum-mitochondrial crosstalk in a Mfn2 mouse 
knockdown model during repetitive high frequency tetanus stimulation. The 
investigators observed that mitochondrial calcium ions were significantly reduced in 
flexor digitorum brevis muscles. An increase in calcium ion transients in the contractile 
portion of muscle tissue, as well as reduced mitochondrial membrane potential were 
further noticed. In a recent study, Xi et al. (2016) demonstrated that Mfn2 is 
downregulated in rectus abdominus biopsies of cancer patients with cachexia, 
whereafter these authors then further explored Mfn2’s role both in vitro and in vivo. 
The in vitro experiments revealed that Mfn2 is downregulated with TNF-α induced 
atrophy in myotubes. In vivo experiments demonstrated that Mfn2 expression was 
decreased in gastrocnemius of mice in a cancer cachexia-induced atrophy model and 
that the overexpression of Mfn2 partially attenuated this muscle loss.  
Melatonin preserved mitochondrial morphology and enhanced Mfn2 expression in 
renal proximal convoluted tubules of mice in an obesity model (Stacchiotti et al. 2014). 
Furthermore, melatonin was also able to enhance Mfn2, DRP-1 and PGC-1α 
expression in rat liver exposed to carbon tetrachloride poisoning (Kang et al. 2016). 
These mitochondrial effects may have been mediated via AMPK, since AMPK 
expression levels were increased with melatonin treatment and reduced in animals 
exposed to carbon tetrachloride alone. 
Accelerated mitochondrial fission is associated with mitochondrial dysfunction in 
cancer cachexia (Youle and van der Bliek 2012).  However, it was found that 
accelerated fission also occurs in healthy muscle during exercise which stimulates 
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mitochondrial biogenesis, possibly via AMPK activation (Romanello et al. 2010). 
These findings may indicate that upregulation of fission is necessary and a positive 
process for mitochondrial adaptation and remodelling in exercised muscle whereas 
fission in cachexia may be even more accelerated and hence has detrimental effects. 
Indeed, the overexpression of the fission protein, hFIS1, in muscle has been 
demonstrated to induce apoptosis, to increase ROS and atrophy in vivo (Romanello 
et al. 2010).  A recent in vitro study by Parameyong et al. (2015), demonstrated that 
melatonin inhibited increases in mitochondrial hFis1 levels in methamphetamine-
induced toxicity of neuronal cells. 
The role of mitophagy in cancer cachexia is still unclear, and it is not known if this 
process is crucial for the maintenance of an efficient mitochondrial network through 
the removal of damaged and redundant mitochondria. Evidence suggests that 
mitophagy is impaired (accumulation of damaged mitochondria) in cancer cachectic 
patients, since a reduction in PTEN-induced putative kinase 1 (PINK1) (marker of 
mitophagy) expression was observed in these individuals together with a trend toward 
Bnip3 (mitophagy regulator) upregulation (Aversa et al. 2016). Marzetti et al. (2017), 
recently showed that mitophagy regulators, PINK1 and Parkin, were both decreased 
in muscle samples from aged gastric cancer patients presenting with cachexia.  
Stellenbosch University  https://scholar.sun.ac.za
53 | P a g e  
 
 
Figure 2.11: The effects of cancer-cachexia induced inflammation on mitochondrial dysfunction in context of 
protein degradation and possible beneficial actions of melatonin. Adapted from VanderVeen et al. (2017). 
In addition to the effects on mitophagy and mitofission, it has been demonstrated in a 
variety of models that melatonin improves mitochondrial function (Vassilopoulos and 
Papazafiri 2005, Petrosillo et al. 2009, Agil et al. 2015), for example in diabetic obese 
rats (Agil et al) in cardiac ischemia-reperfusion injury (Petrosillo et al 2009). In a recent 
in vivo study melatonin was found to enhance mitochondrial biogenesis by increasing 
expression of PGC-1α (Kang et al. 2015). Moreover, melatonin also increased 
mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro (Guo et al. 2014). 
This effect was found to be mediated via the MT1 receptor through the SIRT1-
dependent PGC-1α pathway. SIRT1 activates PGC-1α by deacetylation of lysine 
residues resulting in increased mitochondrial biogenesis (Nemoto et al. 2005, Rodgers 
et al. 2005 and Rasbach and Schnellmann 2008). 
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2.7.9 Melatonin and its effects on skeletal muscle protein degradation: Doxorubicin-
induced toxicity 
Doxorubicin is a very effective chemotherapeutic agent, but myotoxicity limits the 
clinical use of this drug (Sin et al. 2016). The mechanisms of doxorubicin-induced 
myotoxicity is not yet fully understood, however, reactive oxygen species generation 
and long term impairment of mitochondrial respiration appear to be the major 
contributors (Sin et al. 2016). Lissoni, et al. (1999), demonstrated that melatonin 
improved one year survival rates in advanced cancer patients receiving 
chemotherapy. Studies where the effects of melatonin on reducing the toxic effects of 
doxorubicin on striated muscle have been investigated are, however, limited to cardiac 
muscle. Treatment of mice with doxorubicin induced cardiotoxicity using melatonin, 
improved survival rates and significantly improved cardiac function, ultrastructural 
alterations, and inhibited apoptosis (Liu et al. 2002). Ahmed et al. (2005) showed that 
melatonin was cardioprotective and reduced ROS markers and improved the 
antioxidative capacity in rat heart tissue. An excellent recently published review by 
Govender et al. (2017) describes potential mechanisms by which melatonin may 
confer mitochondrial protection against doxorubicin-induced cardiotoxicity.    
The majority of evidence points to the argument that melatonin could potentially 
attenuate skeletal muscle degradation during cancer cachexia and doxorubicin 
treatment; primarily through its antioxidant capacity, thereby providing a possible 
therapeutic mechanism for improving clinical outcome in cancer patients (Lissoni et 
al., 1996, 1999; Srinivasan et al., 2008). However, the role of melatonin on mitophagy 
in the context of doxorubicin-induced skeletal muscle atrophy remains largely unclear.  
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Figure 2.12: Summarized mechanism of DOX-induced myotube atrophy and MLT intervention. ROS, reactive 
oxygen species and MLT, melatonin. Image modified from Gilliam et al. (2015). 
2.7.10 Melatonin and Satellite Cells 
Evidence in literature suggests that melatonin may enhance muscle function by 
enhancing muscle regeneration, directly and indirectly. Melatonin treatment was found 
to increase skeletal muscle fibre diameter and preserve the muscle ultrastructure of 
castrated rats (Oner et al. 2008). In another study, insulin-like growth factor-1 receptor 
(IGF-1R) was significantly over-expressed in melatonin-administered rats in a model 
of stroke induced muscle atrophy, complementing the previous findings (Lee et al. 
2012). 
As mentioned above, melatonin affects mitochondrial biogenesis via PGC-1α. 
Interestingly, in a recent study, it was shown that PGC-1α modulates satellite cell 
number and proliferation by remodelling the stem cell niche (Dinulovic et al. 2016). 
PGC-1α modified the extracellular matrix composition, including the levels of 
fibronectin (Dinulovic et al. 2016). Furthermore, SIRT-1 was shown to act as an 
epigenetic regulator connecting changes in satellite cell metabolism towards myogenic 
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commitment (Ryall et al. 2015). Melatonin could thus potentially regulate satellite cell 
number indirectly via SIRT1 and PGC-1α. 
2.8 Hypothesis revisited 
We hypothesise, that melatonin treatment will prevent doxorubicin-induced skeletal 
muscle atrophy in a rodent tumour-bearing model.  
This hypothesis will be tested using the following models: in vivo rat tumour-bearing 
model of DOX-induced skeletal muscle atrophy and an in vitro C2C12 differentiated 
myotube model of DOX-induced myotoxicity. 
The muscle protective effect of melatonin is likely to occur via multiple mechanisms 
simultaneously, including the attenuation of muscle degradative pathways, the 
stabilization of mitochondrial function and subsequent reduction of ROS levels, 
enhancement of oxygen and nutrient delivery to muscle and by improving muscle 
regeneration during DXR-induced myotoxicity. 
Objective: 
 To assess MLT as a low risk adjuvant therapeutic intervention which can be 
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Chapter 3: Materials & Methods 
3.1 In vivo Study design – Part 1 
3.1.1 Culture of LA7 rat mammary tumour cell line  
Experiments were performed using the rat mammary adenocarcinoma cell line LA7 
(ATCC CRL-2283, Renato Dulbecco, the Salke Institute, San Diego, CA). This cell line 
was a kind gift by Dr A. Krygsman (Stellenbosch University, Stellenbosch, Western 
Cape, RSA). During routine maintenance, cells were grown as monolayers in 
Dulbecco’s Modified Eagles Medium (DMEM, Gibco. Ltd) supplemented with 10% 
foetal bovine serum (FBS, Sigma Chemical Co., St Louis, MO, USA) and 1% 
penicillin/streptomycin (P/S) (Sigma-Aldrich, Johannesburg, South Africa) at 37°C in 
a humidified atmosphere of 95% air plus 5% CO2 in T75 flasks (75 cm2 flasks, Nest 
Scientific, USA) until they reached 80% confluency. LA7 cells were then subcultured. 
Subculturing was accomplished by washing the cell monolayer with warm phosphate 
buffered saline (PBS) followed by incubation with 4 ml trypsin/EDTA (Sigma Chemical 
Co., St Louis, MO, USA) at 37°C, until cells detached completely or for a maximum of 
four minutes. Experiments were performed using exponentially growing cells. 
3.1.2 Animals and interventions 
3.1.2.1 Tumour-bearing rat model 
Sixty, sixteen week old adult female Sprague-Dawley rats (housed in the laboratory 
animal facility at the Department of Physiological Sciences, Stellenbosch University) 
weighing approximately 270 g were used for this study. All animals had access to food 
(standard rat chow, supplied by the Medical Research Council animal unit, Parow) and 
tap water ad libitum. Rats were exposed to a 12 hr light/dark cycle (lights on at 06h00). 
Ambient temperature was controlled at 22ºC, and rooms ventilated at a rate of 10 
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changes/hour.  Prior to the initiation of intervention protocols, rats were accustomed 
to the researcher by frequent handling and weighing before the start of experimental 
procedures. All experimental protocols were approved by the Animal Research Ethics 
Committee of Sub-Committee B of Stellenbosch University (Ethical clearance: SU-
ACUM13-00015).   
 
Figure 3.1: Illustration depicting the position of mammary fat pad no. 4. A 300 ul cell suspension (containing LA7 
16x106 cells) was injected in the lower abdomen of rats, in the no. 4 mammary fat pad.  
Rats were inoculated subcutaneously on the left pad of the fourth mammary gland with 
300 µl of 16x106 LA7 cells suspended in Hanks Balanced Salt Solution (Sigma 
Chemical Co., St Louis, MO, USA), using a 23-gauge needle. This protocol was 
modified and developed from a mouse breast cancer tumour model previously 
established by our research group at Stellenbosch University (Thomas M., PhD thesis, 
University of Stellenbosch and Govender Y., PhD thesis, Stellenbosch University). 
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Figure 3.2: Diagrammatic depiction of experimental procedure. 
 
Figure 3.3: Injection site of Sprague-Dawley rat and typical tumour growth two weeks after injection with LA7 cell 
suspension. 
3.1.2.2 Experimental treatment groups 
Rats were allocated to 6 groups, namely control group; vehicle control group (Hanks 
balanced salt solution); tumour control group; melatonin group; doxorubicin group and 
doxorubicin+melatonin combination group (see Fig. 3.5). 
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Figure 3.4: Experimental design (Abbr. CON - control, VC - vehicle control, TC - tumour control, MLT - melatonin, 
DOX - doxorubicin and DOX+MLT – doxorubicin+melatonin) 
All groups except the control animals (Con) were inoculated with LA7 cells. The vehicle 
control (VC) group received three intraperitoneal injections of Hanks balanced salt 
solution (Sigma Chemical Co., St Louis, MO, USA); the melatonin (MLT) group 
received a daily 6 mg/kg dosage in drinking water after the initial appearance of 
tumours; the doxorubicin (DXR) group received 4 mg/kg dose of doxorubicin 
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intraperitoneally three times over the period of 9 days adding up to a cumulative 
dosage of 12 mg/kg.  
Table 2. Experimental groups and treatments. 
 
3.1.2.2.1 Vehicle administration  
Hanks Balanced Salt Solution (Sigma Chemical Co., St Louis, MO, USA) was used as 
vehicle control and administered three times intraperitoneally over 9 days.  Hanks 
Balanced Salt Solution was first administered after two weeks of tumour growth and 
twice more with three days separating subsequent injections.     
3.1.2.2.2 Melatonin administration & solution preparation 
Rats were housed 5 per cage with one bottle of water per cage. Melatonin (Sigma 
Chemical Co., St Louis, MO, USA) was administered in the drinking water (Lamont et 
al. 2015) daily (a dosage of 6 mg/kg melatonin) from the day of tumour inoculation and 
allowed ad libitum intake.  
Water consumption by the group of animals per cage was monitored and recorded 
one week prior to the start of the study and the average volume of drinking water 
Stellenbosch University  https://scholar.sun.ac.za
62 | P a g e  
 
consumed per animal could be calculated. Water consumption was determined at 50 
ml/rat/day, MLT was dissolved in 700 ml of drinking water at a final concentration of 
30 μg/ml. Water bottles containing MLT were covered with aluminum foil since 
melatonin is a light sensitive and fresh solutions were prepared daily. The dosage of 
6 mg/kg/day was adjusted according to the body weight gain of the animals. Since a 
small volume of MLT was used in this study, it was completely dissolved in the large 
volume of drinking water provided. 
3.1.2.2.3 Doxorubicin administration 
Doxorubicin (Sigma Chemical Co., St Louis, MO, USA) was prepared in Hanks 
Balanced Salt Solution (Sigma Chemical Co., St Louis, MO, USA). It was administered 
intraperitoneal three times, three days apart at 4mg/kg for a cumulative dose of 12 
mg/kg. Doxorubicin was first administered after two weeks of tumour growth and twice 
more with three days separating subsequent injections. 
3.1.2.3 Euthanasia and sample collection 
3.1.2.3.1 Sacrifice 
During the sacrifice procedures, all animals received an overdose of pentobarbitone 
sodium (200 mg/kg i.p.) injection and were exsanguinated. 
3.1.2.3.2 Sample collection 
3.1.2.3.2.1 Blood collection 
Following euthanasia by pentobarbitone overdose, the thorax cavity was opened and 
the heart exposed.  Whole blood samples were obtained from blood in the chest cavity 
after the heart was excised.  Blood was collected using a 5 ml syringe and immediately 
transferred to EDTA-K+ and SST tubes (Vacutainer, Beckton Dickinson). Blood 
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samples were immediately inverted and placed on ice and analysed within 4 hrs 
following collection.   
3.1.2.3.2.2 Muscle collection 
Following blood collection, the gastrocnemius muscle of the right (non-tumour side) 
hind leg was exposed by cutting and removing the skin and connective tissue 
surrounding the muscle. The gastrocnemius muscle was harvested and cut in cross 
section along the muscle belly; one half was processed for immunofluorescence, and 
the other snap-frozen for biochemical analysis. Both the plantaris and soleus muscles 
was fixed and processed for histological analysis.   
 
3.1.3 Sample Analysis 
The analytical profile included the following parameters and procedures: a) serum 
myoglobin (Mb) concentration, b) protein concentration, c) plasma and muscle oxygen 
radical absorbance capacity (ORAC), d) qualitative histological analysis of skeletal 
muscle, e) immunohistochemical staining, f) immunofluorescent staining for 
visualisation of muscle sections for SCs measuring identified by staining for Pax7 
along with appropriate co-stains (see below for detail), g) qualitative histological 
analysis of muscle, h) mitochondria isolation and i) Western blot analysis.  
3.1.3.1 Myoglobin (Mb) concentration 
Serum myoglobin a marker for the presence of muscle damage, was independently 
determined by PathCare pathology laboratory (Medi Clinic, Stellenbosch, Western 
Cape, RSA) using an automated enzymatic method. The normal range for rat Mb 
concentration is 10 – 95 ng/ml at 37oC.    
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3.1.3.2 Whole blood cell differential counts 
Whole blood cell counts were performed using a CELL-DYN 3700 CS Haematology 
Analyser (Abbott Diagnostics, Fullerton, CA) for blood collected in EDTA-K+ tubes 
(Vacutainer, Beckton Dickinson).  
3.1.3.3 Haemotoxylin and Eosin (H&E) 
H&E stained sections were used to qualitatively assess the muscle structure. Using a 
rotary microtome (Leica Microsystems CM1850, Nussloch, Germany) 5 µm muscle 
cross-sections were cut and then stained with H&E.  Haematoxylin stains the 
basophilic structures blue-purple and alcohol-based eosin stains the eosinophilic 
structures bright pink. The basophilic structures include nucleic acids, such as in 
ribosomes and cell nuclei, and cytoplasmic regions rich in RNA.  
3.1.3.4 Histochemistry and immunofluorescence 
All histopathological and immunohistochemical evaluations were conducted on at 
least four rats per time point per treatment group. 
3.1.3.4.1 Histochemistry - Nicotinamide adenine dinucleotide tetrazolium reductase 
(NADH-TR) 
Tissue frozen in isopentane was sectioned at -23°C, 8 µm muscle cross-sections were 
prepared for NADH-TR staining to distinguish between muscle fibre types I and II. Via 
enzymatic activity NADH is reduced to tetrazolium thus forming a formazan precipitate 
which is deposited at sites of mitochondria in the sarcoplasmic network. Type I fibres 
stain darker than type II fibres.   
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3.1.3.4.2 Immunofluorescence 
Cross-sections were labelled with: (a) Pax7 for labelling SCs, (b) laminin for labelling 
muscle membranes and (c) Hoechst for labelling nuclei. PBS controls were also used 
in this part of the study and the antibodies used were specific for rat samples.  For 
appropriate dilutions and suppliers of antibodies used, see Table 2. 
Cross sections of the muscle tissue were cut at 8 µm using a cryostat microtome (Leica 
CM1850 UV, Leica Microsystem Nussloch GmbH, Germany) at -23ºC and mounted 
on slides. The following day, the sections were brought to room temperature, and 
rinsed in 0.01 M phosphate buffered saline containing 0.25% Triton X-100 (15 min) 
and washed with PBS (3 X 5 min). The sections were incubated with Pax7 (1:50; 
mouse monoclonal antibody, Developmental Studies Hybridoma Bank, Iowa City, IA, 
USA) for 1 hour, after which the sections were washed with PBS (3 X 5 min), incubated 
for 1 h at RT with Alexa fluor 488 conjugated secondary antibody (1:250, goat anti-
mouse, Invitrogen, Eugene, Oregan, USA), washed again with PBS (3 X 5 min), 
incubated for 1 h at RT with laminin (1:200, rabbit polyclonal, Z 0097, Dako 
Diagnostech), washed again  with PBS (3 X 5 min) and incubated for 1 h at RT with 
Alexa fluor 594 conjugated secondary antibody (1:250, goat anti-rabbit, Invitrogen, 
Eugene). The sections were then washed in PBS (3 X 5 min), and mounted with the 
fluorescent mounting medium (Dako, Denmark). Samples were observed with a direct 
fluorescence microscope (Leica DM 5000 CTR) using x40 objective. Pax7 positive 
cells were counted in the midbelly region of the whole gastrocnemius muscle. 
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Table 3. List of primary antibodies and secondary fluorescent antibodies used for 
immunofluorescence methods. 
 
3.1.3.5 Protein concentration determination 
To determine muscle total protein concentrations, either for preparing samples for the 
measurement of muscle oxygen radical absorbance capacity (ORAC), western blot 
analysis or to isolate mitochondria, the Direct Detect Infrared Spectrometer (Merck 
Millipore, headquarters Darmstadt, Germany) was used (see section 3.1.7.2). 
3.1.3.6 Antioxidant Capacity - muscle oxygen radical absorbance capacity (ORAC) 
The ORAC assay was performed on homogenised muscle tissue as described by 
Huang et al. (2002). This assay is based on the measurement of oxygen radical-
induced quenching of a fluorescent probe, through the change in the fluorescence 
intensity of the probe in solution over time. Thus, the oxygen radical quenching 
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capacity of the probe in the sample solution can be determined and named ORAC 
(Meeusen and Lievens 1986; Safran et al., 1989; Noonan et al., 1993; Olson and Ley 
2002). The fluorescence probe, fluorescein (F6377, Sigma-Aldrich) and the peroxyl 
radical, AAPH (2,2'azobis(2-amidino-propane) dihydrochloride) (440914, Sigma-
Aldrich) were used to determine the ORAC value. Fluorescence decay is represented 
as the area under the curve (AUC), which was used to quantify total antioxidant 
capacity. The results were then compared to the antioxidant TroloxTM (238813, Sigma-
Aldrich) standard curve and expressed as µmol TroloxTM equivalents (TE) per L of 
sample.  
3.1.3.7 Mitochondrial Isolation 
Mitochondria were isolated from muscle gastrocnemius tissue using a Mitochondria 
isolation kit (ab110169, Abcam). Tissue homogenates were prepared with a Dounce 
homogenizer as indicated in the Abcam kit protocol (ab110169) and protein 
concentration determined as described in section 3.2.2.6. Briefly, 0.2 - 0.4 g of muscle 
tissue was washed, minced and suspended in isolation buffer. Cells were disrupted by 
homogenizing the tissue with 40 dounce strokes after which the homogenate was 
centrifuged at 1000 g for 10 min at 4°C. The supernatant was collected and further 
spun down at 12000 g for 15 min and the pellet was collected, this step was then 
repeated. The pellet was re-suspended in RIPA buffer, aliquoted and frozen at -80°C 
for further analyses. 
3.1.3.8 Western Bot Analysis 
a) Western blot analysis for markers of mitophagy, mitochondrial fission and fusion 
proteins from isolated mitochondria was performed.  
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b) Western blot analysis for markers of Apoptosis, Atrophy, UPP, Autophagy and Ca2+-
dependent cysteine proteases, mitochondrial biogenesis and markers of muscle 
regeneration was performed. 
Protein levels were determined by standard western blot techniques. Briefly, muscle 
homogenates of each sample was prepared, either snap frozen or cryo-sectioned 
tissue in RIPA buffer. Samples were then separated on 4 - 20% precast gradient gels 
and were immunoblotted for apoptotic markers - PARP and Caspase-3, atrophy 
markers – Murf-1 and FoxO3a, autophagy markers – p62, LC3-II and mTOR, Ca2+-
dependent cysteine proteases – Calpain-3.  Total protein was used to determine equal 
loading.  For a full-detailed description of all the reagents used, as well as the protocol 
and method see appendix I.   
3.1.3.8.1 Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE), Electrotransfer and Immuno-detection 
The methodology is described in sections 3.1.7.3. Protein expression was normalized 
to the corresponding total protein per sample. Proteins of interest were detected using 
the manufacturers’ recommended dilutions and the list of primary and secondary 
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Table 4. Primary and enzyme-linked secondary antibodies used for western blot analysis. 
Mitochondrial Isolation 
Primary Antibodies Dilution 
Catalogue number  & 
supplier 
Mitochondrial fission & 
fusion 
  
Mitofusin-1 1:1000 Ab57602, Abcam 
Mitofusin-2 1:1000 Ab57889, Abcam 
OPA-1 1:1000 Ab157457, Abcam 
DRP-1 1:1000 Ab56788, Abcam 
hFis1 1:1000 Ab71498, Abcam 
Mitophagy   
PINK1 1:1000 6946 , Cell Signalling 
PARKIN 1:1000 2132, Cell Signalling 
Crude Extract 
Primary Antibodies Dilution 
Catalogue number  and 
supplier 
Markers of muscle 
regeneration 
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Apoptosis Markers   
c-Caspase3 1:1000 9664, Cell Signalling 
cPARP 1:1000 9541, Cell Signalling 
Atrophy Markers   
FoxO3a 1:1000 9467, Cell Signalling 
MURF-1 1:1000 IMX-3924, IMGENEX 
MAFbx 1:1000 
Sc-33782, Santa Cruz 
Biotechnology 
Autophagy Markers   
LC3-IIB 1:1000 3868, Cell Signalling 
p62 1:1000 8025, Cell Signalling 
pmTOR (Ser2448) 1:1000 ab84400, Abcam 
UPP   
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PGC-1α 1:1000 Ab54481, Abcam 
Sirtuins   







Anti-mouse 1:10 000 7076P2, Cell Signalling 
Anti-rabbit 1:15 000 7074S, Cell Signalling 
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3.1.4 Image Acquisition and Analysis 
Brightfield images were acquired with a Nikon ECLIPSE E400, equipped with a colour 
digital camera (Nikon DXM1200) at 20X magnification. Muscle cross sectional area 
analysis was performed using the ImageJ Java 1.8.0_77 software (National Institute 
of Health, USA) imaging software.  
3.1.5 Statistical Analyses 
Results are presented as means ± standard error of the mean (SEM), unless otherwise 
specified.  Differences between groups were analysed using one-way analysis of 
variance (ANOVA). When significant interactions were found, Bonferroni post hoc 
tests were performed. All statistical analyses were performed using Graph pad Prism 
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3.2 In vitro Study design – Part 2 
 
The mouse myoblast cell line, C2C12, was used to perform the experiments. These 
cells were cultured and differentiated, with 7 treatment groups established i.e. (i) 
control; (ii) vehicle control; (iii) doxorubicin; (iv) melatonin; (v) melatonin pre-treatment 
followed by doxorubicin exposure; (vi) luzindole (a selective melatonin receptor 
antagonist was added together with MLT at a concentration of 50 nM over 48 h (50 
nM 24 h pre-treatment + 50 nM 24 h); and (vii) luzindole & melatonin pre-treatment 
followed by doxorubicin exposure. 
 
Figure 3.5: Schematic representation of the in vitro study design. Differentiated C2C12 myotubes were treated as 
indicated above, and were used to assess various parameters. A Luzindole only group was omitted as seen in 
previous studies (Ha et al. 2006, Quan et al. 2015).  
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3.2.1 Culture of C2C12 mouse cell Line 
 
The mouse myoblast cell line, C2C12 (ATCC CRL-2283, Renato Dulbecco, The Salke 
Institute, San Diego, CA) was used to perform the experiments. C2C12 myoblasts 
were grown as monolayers in Dulbecco’s Modified Eagles Medium (DMEM, Gibco. 
Ltd) supplemented with 10% foetal bovine serum (FBS, Sigma Chemical Co., St Louis, 
MO, USA) and 1 % penicillin/streptomycin (P/S) (Sigma-Aldrich, Johannesburg, South 
Africa) at 37°C in a humidified atmosphere of 95% air plus 5% CO2 in T75 flasks (75 
cm2 flasks, Nest Scientific, USA) for 4 days (media change every two days). Upon 
reaching 80% confluence, cells were serum restricted (2% heat-inactivated horse 
serum, DMEM) and grown for an additional 3 days. On the fourth day following serum 
restriction intervention experiments commenced and myotubes were treated with MLT 
(Sigma Chemical Co., St Louis, MO, USA) and luzindole (Sigma Chemical Co., St 
Louis, MO, USA). On the fifth day myotubes received doxorubicin (Sigma Chemical 
Co., St Louis, MO, USA) treatment and on day six myotubes were harvested for 
biochemical analysis or prepared for staining. 
3.2.2 Differentiated myotube cell culture treatments 
During treatment of myotubes, differentiation medium was replaced with fresh 
differentiation medium containing respective treatments after myotubes were washed 
with a 37°C phosphate buffered saline (PBS) solution. Based on studies in literature 
(Gilliam et al. 2012), cells were treated with DOX at a concentration of 0.8 µM for 24h 
which was used in all in vitro experiments. A cumulative concentration of 100 nM of 
MLT for 48h (50 nM for 24 h + 50 nM for 24 h) was used in all in vitro experiments 
(Maldonado et al. 2016).  
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Myotubes were thus pre-treated with MLT (50 nM) for 24h followed by MLT (50nM) 
and DOX (0.8 µM) the next 24 hours. Luzindole (50 nM, Sigma Chemical Co., St Louis, 
MO, USA) a MLT 1 (MT1) and 2 (MT2) receptor antagonist was added to myotubes 
1h before MLT treatment. A total of seven treatment groups were used for the in vitro 
study as shown in Fig. 3.1 (study design). 
3.2.2.1 Melatonin (MLT) treatment 
A 21.5 mM stock solution of MLT (Sigma Chemical Co., St Louis, MO, US) was 
prepared by dissolving the compound in 50% ethanol. The freshly prepared stock 
solution was dissolved in warm differentiation media to a working solution of 50 nM, 
added to myotubes in appropriate flasks which were covered in foil as MLT is light 
sensitive. Flasks were then incubated for 24h and refreshed with MLT working solution 
for an additional 24h. Since the MLT was dissolved in ethanol, a vehicle control group 
was included in all experiments. The vehicle control group was treated with 0.02% 
ethanol. 
3.2.2.2 Doxorubicin (DOX) treatment 
A stock solution of DOX (Sigma Chemical Co., St Louis, MO, US) at a concentration 
of 3.4 mM was prepared by dissolving the compound in differentiation medium. During 
treatment, DOX was added to fresh warm growth medium to a final concentration of 
0.8 µM. Flasks containing DOX treated myotubes were covered in foil since DOX is 
light sensitive whereafter it was incubated for 24 hours. 
3.2.2.3 Luzindole (LUZ) treatment 
A stock solution of Luzindole (Sigma Chemical Co., St Louis, MO, US) at a 
concentration of 21.5 mM was prepared by dissolving the compound in differentiation 
medium. The freshly prepared stock solution was dissolved in warm differentiation 
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media to a working solution of 50 nM, added to myotubes in appropriate flasks and 
covered in foil. Flasks were then incubated for 24h and refreshed with Luzindole 
working solution for an additional 24h. 
3.2.3 Myotube width  
To measure myotube width, myotubes were tagged with a fluorescent label 
CellTracker™ Green CMFDA CellTracker™ Green CMFDA (5-
chloromethylfluorescein diacetate, Molecular Probes, C7025) freely traverses cell 
membranes into cells and is excited at 492 nm and emits fluorescence at 517 nm, 
where it is transformed into cell membrane-impermeant reaction products. C2C12 
cells were cultured, differentiated and treated as previously described (Figure 3.5) in 
24 well plates (1.9 cm2 plates, Nest Scientific, USA). The myotube width 
measurements is described in section 3.2.8. 
3.2.4 Mitochondrial ROS generation 
ROS generation was assessed using the MitoSOX Red probe (Invitrogen, Molecular 
Probes, M7514). MitoSOX Red is a fluorescent probe used to measure superoxide 
production in the mitochondrial matrix. Due to its cationic properties, MitoSOX Red is 
able to rapidly target the mitochondria, where it is oxidized by superoxide. Oxidation 
of MitoSOX Red yields a fluorescent product known as 2- hydroxymitoethidium, which 
is excited at 510 nm and emits fluorescence at 580 nm. 
Following myotube differentiation and treatment, a 50 µg vial of MitoSOX™ Red 
reagent (Invitrogen, Molecular Probes, M36008) was thawed and allowed to reach 
room temperature before opening. A 50 μg vial of MitoSOX™ mitochondrial 
superoxide indicator was dissolved in 13 μL of dimethylsulfoxide (DMSO) to prepare 
a 5 mM MitoSOX™ reagent stock solution. The stock solution was further dissolved in 
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differentiation media up to a final working concentration of 5 µM; added to cultured 
cells and incubated for 10 mins at 37˚C, while protected from light. Next, myotubes 
were gently washed with warm differentiation medium and fixed in 4% 
paraformaldehyde for 5 mins. The myotubes were then washed with warm PBS and 
wells were sealed fluorescent mounting medium (Dako, Denmark). The culture plates 
were then briefly stored at 4ºC until being imaged.   
3.2.5 Autophagy Kit Assays 
The CYTO-ID® Autophagy Detection kit (ENZ-51031, Enzo Life Sciences) selectively 
labels accumulated autophagic vacuoles and monitors autophagic flux in lysosomal 
inhibited live cells. The probe works as a cationic amphiphilic tracer dye that rapidly 
partitions into cells enabling labelling of vacuoles associated with the autophagy 
pathway without accumulating in lysosomes, possible due to careful selection of 
titratable functional moieties on the dye itself. 
C2C12 cells were differentiated in 96 well plates and appropriately treated (Fig. 3.1). 
Autophagy induction was detected using the Cyto-ID Autophagy detection kit (ENZ-
51031, Enzo Life Sciences) as per the manufacturer’s instruction. Briefly, treated 
differentiated myotubes were plated in biological triplicate in 96 well plates (0.32 cm2 
plates, Nest Scientific, USA) and incubated overnight. Next, myotubes were treated 
with 500 nM rapamycin (positive control) or an equivalent volume of DMSO (negative 
control) for 18 h, after which 60 mM chloroquine was added to each well to enhance 
fluorescence signal. Cells were then washed with 1 × assay buffer and incubated with 
Cyto-ID Green detection reagent and Hoechst 33432. Following incubation, cells were 
washed with 1 × Assay buffer and mean fluorescence signal acquired on a FLx800™ 
Microplate Fluorescence Reader (BioTek™, USA). 
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3.2.6 Immunofluorescence 
Differentiated myoblasts were labelled with: (a) CellTracker™ Green CMFDA (5-
chloromethylfluorescein diacetate, Molecular Probes, C7025) for myotube width 
measurement (see section 3.2.3) (b) MitoSOX Red for labelling mitochondrial ROS 
(see section 3.2.4) and (c) Hoechst 33432 for labelling nuclei.  
3.2.7 Western Blot analysis 
3.2.7.1 Protein extraction and quantification 
Following treatment, myotube supernatant was discarded and placed on ice. Myotube 
monolayers were then washed 3X in 5 mL of pre-lysis buffer (20 mM Tris-HCl, pH 7.4, 
137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 and 0.1 mM sodium orthovanadate). Next, 
myotubes were incubated on ice for 10 mins in 1 mL of modified RIPA buffer (pH 7.4, 
containing: Tris–HCl 2.5 mM, EDTA 1 mM, NaF 50 mM, NaPPi 50 mM, dithiothreitol 1 
mM, phenylmethylsulfonyl fluoride 0.1 mM, benzamidine 1 mM, 4 mg/mL SBTI, 10 
mg/mL leupeptin, 1% NP40, 0.1% SDS and 0.5% Na deoxycholate) to extract total 
cell protein. Adherent cells were then harvested from culture dishes by scraping. The 
resulting lysates were then sonicated to disrupt the cell membranes to release protein 
contents before being centrifuged at 4°C and 8000 rpm for 10 minutes. Lysates were 
next stored at -80°C or had their protein content determined immediately.  
3.2.7.2 Protein Determination and Sample Preparation 
To estimate muscle total protein concentrations, the Direct Detect Infrared 
Spectrometer (Merck Millipore, headquarters Darmstadt, Germany) was used. Direct 
DetectTM Assay-free Cards each contain four slots for loading 2 μl of sample. The first 
slot on all cards was loaded with RIPA buffer which served as a blank reading. Cards 
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were next inserted into the spectrometer and protein content analysed in μg/mL 
following an automated drying cycle of the samples.  
Following protein quantification, aliquots diluted in Laemmli sample buffer were 
prepared for all samples, each containing 20 μg of protein and analysed by western 
blotting. 
3.2.7.3 Sodium Dodecyl-Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE), 
Electrotransfer and Immuno-detection 
After protein concentrations were determined, 20 μg/mL was loaded into each gel and 
separated on 4 - 20% midi-precast gradient gels (Bio-rad). Proteins were separated 
by SDS-PAGE (Midi-PROTEAN®, Biorad) at a constant voltage of 100 V (Biorad 
Power Pac 1000) for 10 minutes (stacking gel), and thereafter at constant voltage of 
200 V for 50 minutes (resolving gel). The separated proteins were transferred to PVDF 
(polyvinylidine fluoride) membranes (Trans-Turbo® midi PVDF transfer pack, 
1704157, Bio-Rad) using the Trans-Blot Turbo System (170-4155, Bio-Rad) at a 
voltage of 12V and constant current of 12A for 10 minutes. Following transfer, 
membranes were washed 3X5 min in TBS-T (TRIS-buffered saline-Tween Solution) 
and non-specific binding sites blocked for one hour in 5% fat-free powdered milk in 
TBS-T (TRIS-buffered saline-Tween Solution), after which membranes were first 
washed and then incubated overnight at 4°C in specific primary antibody solutions. 
Proteins of interest were detected using the manufacturers recommended dilutions 
(see table 3.1). Following overnight incubation, membranes were washed 3X5 min in 
TBS-T and then incubated with their corresponding secondary antibodies at room 
temperature for 1 hour (see table 3.1). The secondary antibodies; HRP-linked anti-
Rabbit secondary antibody (7074, Cell Signalling), Goat anti-Rabbit IgG H&L (HRP) 
secondary antibody (ab97069, Abcam) and Goat anti-Mouse IgG H&L (HRP) 
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secondary antibody (ab97040, Abcam) were utilized. After washing the membranes 
with TBS-T (3X5 min), they were incubated with ClarityTM Western ECL Substrate 
(170-5061, Bio-rad) and exposed with the ChemiDocTM XRS+ System. Densitometric 
analysis was performed with the Image LabTM 5.2.1 Software (Bio-Rad) and protein 
expression was normalized to the corresponding total protein per sample. Antibodies 
were then stripped from membranes in low glycine stripping buffer, pH 2.2 for 2x 5 min 
and membranes re-probed. 
Table 5: Primary and enzyme-linked secondary antibodies used for Western blot analysis. 
 
3.2.8 Image Acquisition and Analysis 
To determine myotube width, five fluorescent images of randomly selected areas were 
captured per well. The mitochondrial ROS assay was similarly conducted and cells 
analysed and analysed for mean fluorescent intensity. Fluorescent signal was 
detected with a Nikon ECLIPSE E400, equipped with a colour digital camera (Nikon 
DXM1200) at the appropriate wavelengths and at 20X magnification.  
All images were analysed using ImageJ Java 1.8.0_77 imaging software (National 
Institute of Health, USA). All values obtained from treated groups were expressed as 
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a percentage of the control values. Three experiments were done in series with 
triplicates for each group.  
3.2.9 Statistical Analyses 
Results are presented as means ± standard error of the mean (SEM). Differences 
between groups were analysed using one-way factorial analysis of variance (ANOVA) 
or two-way factorial analysis of variance (TWO WAY ANOVA), as appropriate. When 
significant interactions were found, Bonferroni post hoc tests were performed. All 
statistical analyses were done using Graph pad Prism 7 (Graph pad Software, Inc., 
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Chapter 4: Results 
4.1 In vivo study  
4.1.1 The effect of MLT and DOX treatment on body mass over time (A) and post-
sacrifice (B) in a tumour-bearing rat model 
 
Rats in the different groups were matched for body mass at the start of the protocol. 
A: A significant reduction in body mass was observed in DOX treated rats on days 10 
[228 ± 6.7 g (p<0.01)], 12 [218 ± 7.3 g (p<0.001)] and 14 [222g ± 6.5 g (p<0.01)] in 
comparison to the MLT group on days 10 [268 ± 8.3 g (p<0.01)], 12 [268 ± 8.0 g 
(p<0.001)] and 14 [271g ± 9.0 g (p<0.01)] and DM days 10 [282 ± 10.1 g (p<0.01)], 12 
[285 ± 7.2 g (p<0.001)] and 14 [284g ± 6.5 g (p<0.01)] groups. B: Post-sacrifice mean 
body mass was significantly (*** p < 0.001) higher in the DM group compared to the 
DOX group (Fig. 4.1.1B). 
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Figure 4.1.1:  Comparison of mean body mass (g) in treated groups (MLT 6 mg/kg or DOX 4 mg/kg or both MLT 
and DOX). (A) Body mass over time and (B) body mass post-sacrifice. Abbreviations- CON: control n = 8; TCON: 
tumour control n = 10 control; VEH: vehicle control n = 8; MLT: melatonin n = 10; DOX: doxorubicin n = 10 and 
DM: doxorubicin+melatonin. n = 10. ** p < 0.01; *** p < 0.001. Data are expressed as mean ± SEM. 
4.1.2 Qualitative comparison of muscle cross sectional area following MLT and DOX 
treatment in a tumour-bearing rat model 
Skeletal muscles were harvested from rats after sacrifice. Tissue histologic features 
were assessed with the use of conventional haematoxylin and eosin (H&E) staining. 
Qualitative assessment showed no major ultrastructural changes between the groups, 
however the DOX group (E) appeared to have smaller muscle cross-sectional at the 
Stellenbosch University  https://scholar.sun.ac.za
84 | P a g e  
 
mid-belly and more compact fibre bundles, when compared to all other groups (Fig. 
4.1.2).  
 
Figure 4.1.2 Representative H&E images of gastrocnemius muscle harvested from rats. Images displayed are 
from (A) Control (CON); (B) Tumour control (TCON); (C) Vehicle (VEH); (D) Melatonin (MLT); (E) Doxorubicin 
(DOX) & (F) Doxorubicin+melatonin (DM). Scale bar represents 100 µm.  
4.1.3 The effect of melatonin and doxorubicin treatment on muscle mass and cross-
sectional area in a tumour-bearing rat model 
At the end of the experimental protocol, rats were sacrificed and rat muscle wet 
weights (soleus, plantaris & gastrocnemius) and CSA’s were recorded.  
4.1.3.1 Soleus muscle weight to body weight ratio and total cross-sectional area 
Rat mean soleus muscle weight & body weight ratios indicated no significant changes 
between groups. Total soleus CSA was determined by analysing H&E stained 
sections, using ImageJ Java 1.8.0_77 software (National Institute of Health, USA). 
Soleus CSA data indicated that the DOX group had a significantly (** p < 0.01) reduced 
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soleus muscle CSA (n=4) compared to the TCON, VEH, MLT and DM groups (Fig. 
4.1.3). 
 
Figure 4.1.3: Comparison of average A) soleus muscle weight (g), B) soleus/body weight ratio (mg/g) and C) total 
soleus cross-sectional area (CSA) between groups. D) Illustration of the soleus muscle for the different groups. *** 
p < 0.01, *** p < 0.001. Data is expressed as mean ± SEM. Abbreviations- CON: control; TCON: tumour control; 
VEH: vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. n = 3-10. 
4.1.3.2 Plantaris muscle weight to body weight ratio and total cross-sectional area 
Rat mean plantaris muscle weight & body weight ratios indicated that the DOX 
treatment led to a significant (* p < 0.05) reduction in plantaris muscle weight & body 
weight compared to the MLT and DM groups. Total plantaris muscle CSA was 
Stellenbosch University  https://scholar.sun.ac.za
86 | P a g e  
 
determined by analysing H&E stained sections, using ImageJ Java 1.8.0_77 software 
(National Institute of Health, USA). Plantaris muscle CSA was significantly (** p < 0.05) 
reduced in the DOX group compared to the CON and MLT groups (Fig. 4.1.4). 
 
Figure 4.1.4: Comparison of average A) plantaris muscle weight (g), B) plantaris/body weight ratio (mg/g) and C) 
total soleus cross-sectional area (CSA) between groups (µm). D) Illustration of the plantaris muscle for the different 
groups. Data is expressed as mean ± SEM; * p < 0,05; ** p < 0.01 ; *** p < 0.001. Abbreviations- CON: control; 
TCON: tumour control; VEH: vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
n = 3-10. 
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4.1.3.3A Gastrocnemius muscle weight and body weight ratio 
Analyses of the rat mean gastrocnemius muscle weight & body weight ratios indicated 
that the DOX group had significantly (*** p < 0.001) reduced gastrocnemius muscle 
weight compared to the MLT and DM groups (Fig. 4.1.5).  
 
Fig. 4.1.5: Comparison of average A) gastrocnemius muscle weight (g) and B) body weight ratio (mg/g) between 
groups. C) Illustration of the gastrocnemius muscle for the different groups. *** p < 0.01, *** p < 0.001. Data is 
expressed as mean ± SEM. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: 
melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. n = 3-10. 
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4.1.3.3B Gastrocnemius muscle cross-sectional area 
Gastrocnemius muscle CSA was quantitatively assessed with the use of NADH- 
tetrazolium reductase (NADH-TR) histochemical stain. The DOX treated group had 
significantly decreased type I muscle fibre CSA compared to all other groups. Similarly 
the DOX treated group displayed significantly decreased type II muscle fibre CSA 
compared to all other groups, excluding the TCON group (Fig. 4.1.6).   
 
Figure 4.1.6: A) NADH-TR stained gastrocnemius muscle: I = dark type I fibres and II = light type II fibres. B) 
Differences in fibre-specific cross-sectional area (CSA). The dotted and blocked bars indicate changes in CSA 
(um2) for type I and type II fibres respectively. *significantly different from CON, (** p < 0.05) and † significantly 
different from DOX, (* p < 0.05). Data are expressed as mean ± SEM. Abbreviations- CON: control; TCON: tumour 
control; VEH: vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. n = 3-10. Scale 
bar represents 100 µm. 
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4.1.4 The effect of melatonin and doxorubicin treatment on blood parameters in a 
tumour-bearing rat model 
4.1.4.1 Serum Myoglobin (Mb)  
Serum Myoglobin (Mb) levels were significantly increased when treating with DOX, 
compared to MLT and DM groups (* p < 0.05) groups (Fig. 4.1.7).  
 
 
Figure 4.1.7: Difference in serum myoglobin (Mb) levels between groups. Data are expressed as mean ± SEM; * 
p < 0.05; ** p < 0.01. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: melatonin; 
DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.4.2 Differential whole blood counts 
WBCs (1.49 ± 0.4 x 109L-1, * p < 0.05), neutrophils (1.6 ± 0.5 x 109L-1, * p < 0.05), 
RBCs (4.0 ± 1.52 x 1012L-1, * p < 0.05), haematocrit (39 ± 10.43 x 1012L-1, * p < 0.05) 
and haemoglobin (8.3 ± 2.22 x 1012L-1, * p < 0.05) levels were significantly decreased 
in the DOX group compared to all other groups (Table 3). Eosinophil levels were 
significantly increased in the TCON [0.4 ± 0.20 x 109L-1 (* p < 0.01)] and VEH [0.3 ± 
0.20 x 109L-1 (* p < 0.01)] group compared to the DOX group [0.04 ± 0.33 x 109L-1 (* p 
< 0.01)]. Lymphocytes [2.2 ±2.3 x 109L-1 (* p < 0.05)] in the DM group were significantly 
increased when compared to CON [0.04 ± 0.03 x 109L-1 (* p < 0.01)] and MLT [0.1 ± 
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0.1 x 109L-1 (* p < 0.01)]. Basophil levels were significantly increased in the MLT group 
[0.1 ± 1.40 x 109L-1 (* p < 0.01)] compared to the TCON group [0.003 ± 0.003 x 109L-
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Table 6: Leukocyte (WBC) and red blood cell (RBC) indices in peripheral blood following MLT 
and DOX treatment in a tumour-bearing rat model.  





























































































































Abbreviations- WBC: white blood cell; RBC: red blood cell; CON: control; TCON: tumour control; VEH: vehicle 
control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. * p < 0.05 compared to DOX; ᴪ p < 
0.05 compared to DM; # p < 0.05 compared to DOX. Data is expressed as mean ± SEM.  
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4.1.5 The effect of melatonin and doxorubicin treatment on muscle injury and 
degradation processes in a tumour-bearing rat model 
4.1.5.1 Apoptosis 
A significant increase in cCaspase3 expression was evident in the DOX group 
compared to CON (* p < 0.05). The TCON group was significantly decreased from the 
MLT (* p < 0.05), DOX (* p < 0.001) and DM (* p < 0.05) groups. No significant 
differences between groups were observed in cPARP protein levels (Fig. 4.1.8). 
 
Figure 4.1.8: Apoptosis marker protein levels A) cCaspase3 and B) cPARP. Below bar graphs A and B are 
illustrations of protein bands.  Values are expressed relative to the control values (mean ± SEM). *** p < 0.001, n 
= 3-10, average n = 8. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: melatonin; 
DOX: doxorubicin and DM: doxorubicin+melatonin. 
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4.1.5.2 Atrophy 
MAFbx protein levels were significantly reduced in the DM group compared to all other 
groups, while a significant increase in MuRF1 protein expression was evident in the 
DOX treated groups compared to CON (* p < 0.05). FoxO3a protein levels were 
significantly increased in the DOX group compared to CON and DM groups (Fig. 
4.1.9). 
 
Figure 4.1.9: Atrophy marker: MAFbx, MuRF-1, FoxO-1 & FoxO3a protein levels. Values are expressed relative 
to the control values (mean ± SEM).* p < 0.05, ** p < 0.01, *** p < 0.001 n = 3-10. Abbreviations- CON: control; 
TCON: tumour control; VEH: vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
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4.1.5.3 Ubiquitin proteasome pathway (UPP) 
No significant changes were observed for UPP markers; K48 and K63 protein levels 
(Fig. 4.1.10). 
 
Figure 4.1.10: Markers of the ubiquitin proteasome pathway. Values are expressed relative to the control values 
(mean ± SEM), n = 5-7. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: melatonin; 
DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.5.4 Autophagy 
Key proteins involved in autophagy were assessed, namely A) Phospho-mTOR; B) 
p62 and LC3-I to LC3-II conversion were assessed by western blot analysis. Phospho-
mTOR protein levels were significantly increased in the DOX group compared to the 
Stellenbosch University  https://scholar.sun.ac.za
95 | P a g e  
 
CON (*p < 0.05). p62 protein levels were significantly increased (*p < 0.05) in the DOX 
group as compared to the DM group; whereas LC3-I to LC3-II conversion was 
significantly (*** p < 0.001) decreased in the DOX group compared to all the other 
groups (Fig. 4.1.11).  
 
Figure 4.1.11: Markers of the autophagy pathway. Values are expressed relative to the control values (mean ± 
SEM). *p < 0.05; ** p < 0.01; *** p < 0.001, n = 3-10. Abbreviations- CON: control; TCON: tumour control; VEH: 
vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
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4.1.5.5 Calpain System 
Ubiquitously expressed and skeletal muscle specific Calpain: 
Western blot analysis revealed no significant differences between groups in protein 
levels of ubiquitous non-lysosomal, Ca2+-dependent cysteine proteases, Calpain-1 or 
2. While Calpain-3 protein level was significantly higher (* p < 0.05) in the DOX group 
compared to the MLT and DM groups (Fig. 4.1.12). 
 
Figure 4.1.12: Ubiquitously expressed calpain-1 (A), calpain-2 (B) and skeletal muscle specific calpain-3 (C) 
protein levels protein levels. Values are expressed relative to the control values (mean ± SEM), * p < 0.05, n = 3-
10. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: melatonin; DOX: doxorubicin 
and DM: doxorubicin+melatonin. 
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4.1.6 The effect of melatonin and doxorubicin treatment on muscle antioxidant 
capacity in a tumour-bearing rat model 
Intramuscular Oxygen Radical Absorbance Capacity indicated that both MLT and DM 
treatment groups had significantly (* p < 0.05) increased muscle ORAC levels 
compared to all the other groups. No significant difference was observed between the 
CON and DOX group (Fig. 4.1.13).  
 
Figure 4.1.13: Intramuscular gastrocnemius antioxidant capacity of treatment groups. * p < 0.05; ** p < 0.01. Data 
are expressed as mean ± SEM. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: 
melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. n = 3-10. 
4.1.7 The effect of melatonin and doxorubicin treatment on mitochondrial biogenesis 
in a tumour-bearing rat model 
Mitochondrial biogenesis marker PGC-1α protein levels were significantly decreased 
in the DOX group compared to the Control (*p < 0.05), MLT (** p < 0.01) and DM (*** 
p < 0.001) groups (Fig. 4.1.14). 
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Figure 4.1.14: PGC-1α protein levels in skeletal muscle. Values are expressed relative to the control values (mean 
± SEM). * p < 0.05; ** p < 0.01; ** p < 0.001, n = 3-10. Abbreviations- CON: control; TCON: tumour control; VEH: 
vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.8 The effect of melatonin and doxorubicin treatment on mitochondrial dynamics in 
a tumour-bearing rat model 
4.1.8.1 Fission protein 
 
Mitochondrial fission protein marker, Hfis1, expression showed no significant changes 
between groups (Fig. 4.1.15). 
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Figure 4.1.15: Hfis1 protein levels in skeletal muscle. Values are expressed relative to the control values (mean ± 
SEM). * p < 0.05; ** p < 0.01, n = 3. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; 
MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.8.2 Fusion proteins 
 
Mitochondrial fusion markers A) mitofusin1 (Mfn1) and B) mitofusin (Mfn2) protein 
levels. No significant difference was observed in Mfn1 protein levels, whereas Mfn2 
protein levels in the DM group was significantly (* p < 0.05) decreased compared to 
the control group (Fig. 4.1.16). 
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Figure 4.1.16: Mitofusion protein levels in skeletal muscle. Values are expressed relative to the control values 
(mean ± SEM). * p < 0.05, n = 3-5. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: 
melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.9 The effect of melatonin and doxorubicin treatment on marker PTEN-induced 
putative kinase 1 in a tumour-bearing rat model 
PINK1 is a mitochondrial serine/threonine kinase which protects cells from stress 
induced mitochondrial dysfunction. A significant (* p < 0.05) increase was observed in 
PINK1 protein levels in the MLT group compared to all other groups (Fig. 4.1.17). 
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Figure 4.1.17: PINK1 protein levels in skeletal muscle. Values are expressed relative to the control values (mean 
± SEM). * p < 0.05, n = 3. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: 
melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.10 The effect of melatonin and doxorubicin treatment on muscle satellite cell 
number in a tumour-bearing rat model 
The satellite cell marker, Pax7, was used to determine satellite cell number per 
myofibre (section 4.1.12.1) and Pax7 protein levels in skeletal muscle (section 
4.1.12.2).  
4.1.10.1 Pax-7 positive cell count  
Pax-7 is a marker expressed on quiescent satellite cells (Cornelison and Wold 1997, 
Scime and Rudnicki 2006). MLT caused a significant (* p < 0.05) increase in satellite 
cells per myofibre. No significant difference was detected when DOX was compared 
with the control group. Pax7 protein levels significantly (* p < 0.05) increased in both 
the MLT and DM group compared to the control group, thus mimicking the Pax7 
positive cell count result (Fig. 4.1.18). 
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Figure 4.1.18: Pax7 positive cell count. A) Example of satellite cell – i) Hoechst 33342 stained nuclei; ii) FITC anti-
Pax7; iii) Texas Red anti-Laminin and iv) image overlay. B) Differences in average satellite cell/myofibre ratio 
between groups. C) Pax7 protein levels in skeletal muscle. * p < 0.05; ** p < 0.01, n = 3-9. Data are expressed as 
mean ± SEM. Abbreviations- CON: control; TCON: tumour control; VEH: vehicle control; MLT: melatonin; DOX: 
doxorubicin and DM: doxorubicin+melatonin. 
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4.1.10.2 Markers of myogenic regulation 
Western blot analysis of Myogenin and MyoD protein levels. MyoD protein levels were 
significantly (*p < 0.05) higher in the DOX group compared to the MLT group (Fig. 
4.1.19). 
 
Figure 4.1.19: A) Myogenin and B) MyoD protein levels in skeletal muscle. Values are expressed as arbitrary units 
(mean ± SEM). Significance (** p < 0.01), n = 3-5. Abbreviations- CON: control; TCON: tumour control; VEH: 
vehicle control; MLT: melatonin; DOX: doxorubicin and DM: doxorubicin+melatonin. 
4.1.11 The effect of melatonin and doxorubicin treatment on muscle sirtuin 1 and 3 
protein levels during in a tumour-bearing rat model 
SIRT-3 protein levels in the DOX treated groups were significantly increased 
compared to the CON group (Fig. 4.1.20). 
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Figure 4.1.20: A) SIRT-1 and B) SIRT-3 protein levels in skeletal muscle mitochondrial extract. Values are 
expressed relative to the control values (mean ± SEM). Significance (* p < 0.05; ** p < 0.01), n = 3-5. 
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4.2 In vitro Study  
4.2.1 Inhibition of Melatonin Receptor 
To establish whether melatonin acts through its receptor two additional treatment 
groups were added, i.e. MLT+luzindole and MLT+DOX+ luzindole. Luzindole inhibits 
the MT1 receptor and partially inhibits the MT2 receptor. Myotube diameter was 
assessed by analysing 2D images with ImageJ using the FITC Celltracker green to 
label myotubes (Fig. 4.2.1&2).  
4.2.1.1 Qualitative observations of myotubes 
Upon visual inspection, myotubes in the MLT and DM groups had increased tube 
diameter compared to all other groups. The DOX group possessed less differentiated 
myotubes as more single nuclei were observed in this group, whereas the DMI group 
had more differentiated tubes which were decreased in diameter but more pronounced 
in length (Fig. 4.2.1). 
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Figure 4.2.1: A comparison of myotubes in all treatment groups: A) CON; B) VEH; C) MEL; D) DOX; E) DM; F) MI 
and G) DMI. Abbreviations- CON: control; VEH: vehicle; MLT: melatonin; DOX: doxorubicin; DM: DOX+MLT; MI: 
MLT+luzindole; DMI: DOX+MLT+luzindole. Myotubes were labelled with FITC Celltracker green and Hoechst 
(nuclei). Scale bar represents 100 µm. 
4.2.1.2 Quantitative analysis of myotube diameter 
Myotube width in the control group was significantly increased compared to the DOX 
group and significantly reduced compared to the DM group.  The MLT group myotube 
widths were significantly increased compared to all groups except the control and DM 
groups. Moreover, the DM group displayed thicker myotube formation compared to all 
other groups except the MLT group (Fig. 4.2.2).  
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Figure 4.2.2:  A comparison of mean myotube diameter (um) in treatment groups: A) CON; B) VEH; C) MEL; D) 
DOX; E) DM; F) MI and G) DMI. Abbreviations- CON: control; VEH: vehicle; MLT: melatonin; DOX: doxorubicin; 
DM: DOX+MLT; MI: MLT+luzindole; DMI: DOX+MLT+luzindole. Mean myotube tube diameter analysed.  
4.2.2 The effect of melatonin and doxorubicin treatment on mitochondrial reactive 
oxygen species generation 
Below are representative images showing MitoSOX red fluorescent signal in myotubes 
in the treatment groups (Fig. 4.2.3). MitoSOX red fluorescent signal intensity was 
brightest in the DOX group (Fig. 4.2.3 - D) and significantly (** p < 0.01) elevated 
compared to all other groups (Fig. 4.2.3).  
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Figure 4.2.3: A comparison of mitochondrial ROS production in treatment groups. i) Myotubes were labelled with 
MitoSOX red and Hoechst (nuclei), and were overlaid with phase contrast images. Representative Images (A) 
CON; (B) VEH; (C) MLT; (D) DOX, (E) DM, (F) MI & DMI. ii) The data indicate the relative red fluorescence intensity. 
Data represent the mean from three wells, 100 µm scale. Abbreviations- CON: control; VEH: vehicle; MLT: 
melatonin; DOX: doxorubicin; DM: doxorubicin+melatonin; MI: melatonin+luzindole; DMI: 
dox+melatonin+luzindole. 
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4.2.3 The effect of melatonin and doxorubicin treatment on mitochondrial sirtuin levels 
A significant (* p < 0.05) increase in SIRT3 expression was evident in the DOX and MI 
group compared to the control (Fig. 4.2.4).  
 
 
Figure 4.2.4: Mitochondrial SIRT3 expression. Values are expressed relative to the control values (mean ± SEM). 
* p < 0.05, n = 3. Abbreviations- CON: control; VEH: vehicle; MLT: melatonin; DOX: doxorubicin; DM: 
doxorubicin+melatonin; MI: melatonin+luzindole; DMI: doxorubicin+melatonin+luzindole. 
4.2.4 The effect of melatonin and doxorubicin treatment on protein degradation 
through autophagy. 
4.2.4.1 Autophagy 
4.2.4.1.1 CYTO-ID detection kit 
The DOX group showed a significantly increased response in chloroquine (** p < 0.01), 
indicating autophagy inhibition, and the rapamycin (autophagy inducer) + chloroquine 
(*p < 0.05) treatment, from control levels. Furthermore, rapamycin treatment was 
significantly decreased compared to both chloroquine (* p < 0.05) and the 
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rapamycin+chloroquine (* p < 0.05) treatment in this group. The DM group had a 
significantly (* p < 0.05) increased response in chloroquine treatment from control 
levels (* p < 0.05), whereas the rapamycin treatment was significantly decreased 
compared to chloroquine treatment (Fig. 4.2.5). 
 
 
Figure 4.2.5: Detection of autophagy by microplate reader in myotubes. Myotubes were cultured with DMSO 
(control), 0.5 uM rapamycin, or 0.5 uM rapamycin+ 10 uM chloroquine (CLQ) for 18 hours, followed by staining 
with green detection reagent as described in the manual. Nuclei were counter stained with Hoechst 33342. The 
data indicate the relative green fluorescence intensity normalized by blue fluorescence intensity. Data represent 
the mean from three wells. Abbreviations- CON: control; VEH: vehicle; MLT: melatonin; DOX: doxorubicin; DM: 
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Chapter 5: Discussion 
The role of melatonin (MLT) in doxorubicin (DOX)-induced skeletal muscle atrophy 
has not previously been investigated in a clinically relevant tumour-bearing model. 
There is currently a lack of information regarding the effect of MLT treatment on 
mitochondrial function during DOX-induced myotoxicity, as well as its role during 
muscle regeneration. This thesis aimed to provide insight into the effect of MLT on cell 
death, autophagy/mitophagy, mitochondrial fission and fusion, mitochondrial 
biogenesis, sirtuin levels, and muscle degradation and regeneration processes.   
5.1 In vivo study 
5.1.1 DOX treatment reduces body mass and skeletal muscle cross sectional area 
(CSA) 
Cachexia is a syndrome of involuntary weight-loss, distinguished by progressive loss 
of fat mass, skeletal muscle and functional impairment (Ohnuma and Adigun 2017). 
The cachectic state can be induced by the condition of cancer (Mattox 2017) or due 
to chemotherapeutic toxicity (Wang et al. 2015, Rasanen et al. 2016). The in vivo 
model used in this study was modified from a xenograph mouse breast cancer tumour 
model previously established by our research group at Stellenbosch University (Dr 
Mark Thomas, PhD thesis, 2012). Results from that mouse model showed that mice 
in the tumour control group had significantly reduced body mass and reduced soleus, 
plantaris and gastrocnemius muscle weights and cross sectional areas compared to 
the group that bore no tumour. Although tumour growth over time was apparent in both 
models, no differences in body weight was observed between the control and tumour 
control groups in the current study (Fig. 4.1.1B).  
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It is now evident that muscle atrophy induced by cancer and chemotherapy follow 
similar signalling pathways (Barreto et al. 2016). However, the current results indicate 
that soleus (Fig. 4.1.3A), plantaris (Fig. 4.1.4A) and gastrocnemius (Fig. 4.1.5A) 
muscle weights and cross sectional areas (Fig. 4.1.3C, Fig. 4.1.4C and Fig. 4.1.6B) in 
the tumour control group were also not significantly different from the control group, 
except for a significant (* p < 0.05) reduction in Type I slow oxidative fibres of the 
gastrocnemius muscle (Fig. 4.1.6B). These results, taken together, indicate that 
cancer cachexia was not achieved with the current model. This could perhaps be due 
to the shorter time period in which the tumour was allowed to grow or the number of 
cells used to inoculate the rats. Muscle wasting has been well characterized in rodent 
models of cancer and a high incidence is also seen among patients with gastric, 
pancreatic, lung and colorectal tumours (Tan and Fearon 2008). Rat models include 
Walker 256 carcinosarcoma, Morris hepatoma 7777, Yoshida ascites hepatoma 130 
(AH130); whilst murine models include the MCG 101, murine adenocarcinoma 16 
(MAC16), human melanoma, C26 colorectal adenocarcinoma and the most commonly 
used Lewis lung carcinoma model (Mueller et al. 2016, Holecek et al. 2012). It was 
also previously shown that a MCF-7 xenograft model of breast cancer induced 
profound cachexia (Kumar et al. 2003). In order to test the effectiveness of anti-
cachexia compounds, models should more closely mimic the clinical complexities by 
ideally including chemotherapy treatment. 
In the current study, rats began DOX treatment 14 days after tumour inoculation. The 
rats treated with DOX demonstrated a 22.5%, 5.6%, 25.8% and 26.8% reductions in 
means of body mass at sacrifice (Fig. 4.1.1B), soleus (Fig. 4.1.3A), plantaris (Fig. 
4.1.4A) and gastrocnemius (Fig. 4.1.5A) muscle weights respectively compared to 
control. This was despite only 9 days of DOX treatment. Our data thus, confirmed the 
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cachectic state, as defined by Strasser (2008):  a loss of more than 5% of body mass 
in the previous 6 months. This is taken as a defining point for cachexia where death 
usually occurs in patients when there is 30% weight loss (Tisdale 2002). DOX-induced 
skeletal muscle atrophy in this model is further confirmed when determining muscle 
weight to body weight ratios. The muscle weight to body weight ratios for both plantaris 
(Fig. 4.1.4B) and gastrocnemius (Fig. 4.1.5B) muscles were significantly decreased 
when compared to controls. This finding is supported by qualitative (Haematoxylin and 
eosin staining, Fig. 4.1.2) and quantitative (CSA analysis of NADH-TR stained muscle 
fibres) histology of the general structure of gastrocnemius muscle which showed that 
both slow and fast twitch muscle fibre CSA’s were significantly reduced by the 
chemotherapeutic agent (control Type I: 906.81±73.86 & Type II: 2073.±73.86) (DOX 
Type I: 504.11±92.78 & Type II: 1281.87±230.07) compared to CON (Fig. 4.1.6A&B). 
Hydock et al. (2011), showed that muscle mass of both soleus (mainly type I fibres) 
and extensor digitorum longus (mainly type II fibres) decreased with DOX treatment in 
rats, similar to what was found in the current study. The group was also able to show 
that the degree of dysfunction was greater in the soleus muscle (Hydock et al. 2011), 
which brings up the question why type II fibres would be more protected from DOX-
induced myotoxicity? It might be due to the fact that DOX is more localised in type I 
fibres since mitochondrial densities are greater compared to type II fibres thus less 
ROS damage is experienced by type II fibres. Other possible reasons could be that 
type II fibres contain larger sized motor neurons or that antioxidant defence capacity 
is greater. This question and these proposed assertions remain to be fully elucidated. 
Direct injection of DOX into skeletal muscle has been found to result in reduced cross 
sectional areas (CSA) of sternocleinomastoid muscle of rabbits (McLoon et al. 1998) 
and permanent muscle loss in eyelids of patients who suffer from hemi-facial and 
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blepharospasm (Wirtschafter and McLoon 1998). Moreover, it was shown in several 
studies that intravenous administration of DOX resulted in a reduction of body weight 
in two different rodent models (Hajjaji et al. 2012, Rasanen et al. 2016) which was 
shown in a different study to be mainly due to skeletal muscle tissue loss (Nissinen et 
al. 2016). These observed effects might have been due to a reduction in food intake 
since clinical side effects of the drug include nausea and loss of appetite (Braun et al. 
2014); which induce a systemic hypercatabolic state (Baracos 2006). Although 
enforced reduction of food intake in other groups of rodents could control for DOX-
induced effects on appetite, the current studies focussed on elucidating mechanisms 
of effect that were largely not proposed to be affected by caloric intake.  
5.1.2 MLT and DOX treatment effects in circulation   
When studying skeletal muscle wasting induced by cancer cachexia, DOX or both 
cancer cachexia and DOX as treatment, it is important to not only consider skeletal 
muscle in isolation, since the cardiovascular system is also affected due to systemic 
inflammation present during cancer cachexia and cardiotoxicity caused by DOX 
(Braun et al. 2014 and Kazemi-Bajestani et al. 2014). A compromised cardiovascular 
system has direct effects on skeletal muscle, since oxygen and nutrient supply to 
skeletal muscle would decline resulting in a hypoxic environment and reduced 
oxidative metabolism which may be directly related to cachectic patient muscle 
weakness and fatigue.  
Myoglobin, the iron binding and oxygen carrier in muscle, was significantly increased 
in circulation with DOX treatment (Fig. 4.1.7). This indicates that muscle membrane 
structure was compromised resulting in the leakage of this marker into circulation 
(Macaluso et al. 2014). It was shown previously that the transcription factor Mef2C 
was downregulated in skeletal muscle of cachectic mice (Shum et al. 2012). This 
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transcription factor is important for myogenesis and since the myoglobin gene is also 
a target of Mef2C, Shum et al. (2012) speculated that it may be associated with 
decreased oxygen transport capacity and reduced ATP generation. There would thus 
be a double complication with regard to myoglobin for patients if it was found that 
myoglobin is also high in circulation of patients on DOX treatment, as was found here 
in rodents. As previously mentioned, DOX has a binding affinity for iron (Mjos et al. 
2015) and in the centre of myoglobin’s structure an iron atom resides in the ferrous 
oxidation state (Arcon et al. 2015) to which oxygen directly binds. Oxidation of this 
molecule results in the inability to normally bind oxygen. This could therefore be a third 
aspect of burden.  
A hallmark of cancer cachexia is anaemia which presents with haemoglobin levels of 
< 12 g/dl, occurring in almost 40% of cancer patients (Knight et al. 2004). Anaemic 
patients present with symptoms of fatigue, paleness of the skin, shortness of breath 
(Jelani and Katz 2010), and it is thought that DOX may induce anaemia independently 
of cancer cachexia (Bhinge et al. 2012). Haemoglobin has a similar structure to 
myoglobin and transports oxygen in circulation; at muscle tissue it offloads its oxygen 
to myoglobin which further transports oxygen within muscle. Interestingly, 
haemoglobin levels were also significantly reduced in the DOX treated group (Table 
3) which indicates that reduced oxygen is supplied to muscle tissue with potentially 
compromised myoglobin molecules. The oxygen transport burden from lungs to 
mitochondria could therefore be four-fold. 
In the current study serum myoglobin levels were significantly increased in the DOX 
group alone (Fig. 4.1.7). MLT treatment prevented myoglobin leakage into circulation 
indicating a muscle membrane protective effect, since the DM group myoglobin levels 
were also at control levels (Fig. 4.1.7). Furthermore, haemoglobin levels (Table 3) 
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were significantly reduced in the DOX treatment group. MLT also prevented the DOX-
induced haemoglobin (Table 3) reduction (Table 3), further sparing oxygen carrying 
capacity to and in the muscle. This might be due to its antioxidant effects. Free radical 
formation can be blunted due to oxygen oxidation of ferrous iron to ferric iron in both 
myoglobin and haemoglobin; or potentially by directly interacting with DOX in 
membranes, thus preventing damage to the myocyte membranes and structures 
(Costa et al. 1997, Alves et al. 2017). Further evidence for this is that the haematocrit 
levels and RBC number (Table 3) improved in MLT treated rats in opposition to the 
significant reductions observed in DOX treated animals. This might indicate that MLT 
is able to rescue the myelosuppressive effects of DOX (Chen et al. 2017). A study by 
Pin et al. (2015), who co-administered erythropoietin (to prevent anaemia) together 
with mild exercise in tumour-bearing mice, found that oxidative muscle fibres were 
spared from atrophy. The combination treatment was found to lessen muscle strength 
loss and prevented mitochondrial ultrastructural alterations, while it increased 
oxidative capacity and ATP content (Pin et al. 2015). 
MLT treatment also increased WBC, neutrophil and eosinophil numbers compared 
with control levels (Table 3), while these parameters were significantly reduced with 
DOX. The eosinophil counts of the tumour control and vehicle groups were 
significantly greater than that of the DOX group and higher than control and MLT 
treated groups (Table 3), which could be explained by tumour-associated tissue 
eosinophilia and tumour-associated blood eosinophilia (associated with metastasis 
and a poor prognosis) which have been described in a variety of tumour types (Lowe 
et al. 1981). Both neutrophils and eosinophils are required for muscle regeneration, as 
these cells are recruited to muscle damage sites to rapidly clear cellular necrotic 
debris. It has also been shown that eosinophils are essential for muscle repair as it 
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secretes cytokines which activate the regenerative actions of muscle resident 
fibro/adipocyte progenitors  thus forming an adaptive niche for proliferating satellite 
cells in regenerating muscles (Heredia et al. 2013). The basophil count was 
significantly increased in the MLT group alone compared to all other groups. Basophils 
release the vasodilator, histamine, which is able to increase blood flow to tissues to 
improve oxygen and nutrient delivery to muscle. The results of the peripheral WBC 
differential counts should be compared with results of intramuscular levels of WBC to 
make further conclusions which should be undertaken in future studies. 
5.1.3 Improvement of muscle antioxidant capacity by MLT 
MLT is an unique antioxidant since it is capable of scavenging a range of different 
radicals, while its metabolites also possess antioxidant properties (Zang et al. 1998, 
Zhang and Zhang 2014). MLT not only scavenges free radicals, but it was also shown 
to improve antioxidant defence systems in muscle (Leonardo-Mendonca et al. 2017).  
Intramuscular muscle antioxidant capacity was significantly increased in the MLT 
treated groups compared to all other groups (Fig. 4.1.13), which highlights the free 
radical (Zhang and Zhang 2014) scavenging properties of MLT. It is important to note 
that ROS is important for normal cell function and should be modulated within 
homeostatic ranges. Unlike many other antioxidants, MLT not only reduces ROS but 
may act as ‘conditional’ pro-oxidant and increase ROS as demonstrated in some in 
vitro studies (Zhang and Zhang 2014), suggesting that MLT could potentially buffer 
ROS levels. This characteristic of MLT is concentration dependent, cell type 
dependent, is not correlated with cytotoxicity and is mostly observed in cancer cells.  
ROS stimulated catabolism of myotubes has been shown to result in reduced myosin 
and sarcomeric actin in vitro (Gilliam et al. 2012). Increased ROS levels can directly 
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damage myocytes or indirectly via the stimulation of catabolic signalling. The 
mitochondria are major sights of ROS generation and MLT and its metabolites have 
been shown to protect the electron transport chain and mitochondrial DNA from 
oxidative damage thus preserving energy production (Coto-Montes et al. 2016).  
MLT may improve antioxidant capacity since one MLT molecule is capable of 
scavenging multiple reactive oxygen species (Tan et al. 2002). Moreover, MLT may 
be improving intramuscular antioxidant defence capacity by supporting several other 
local antioxidant enzymes, as it has previously been shown to stimulate the production 
of the antioxidant, glutathione (Korkmaz et al. 2008), the most abundant non-protein 
thiol in cells with intracellular concentrations of 1–10 mM (Smith et al. 1996). This 
capability of MLT to enhance tissue resident antioxidant defences is crucial since a 
growing body of evidence show that antioxidant supplementation may induce muscle 
atrophy by downregulating endogenous antioxidant defences (Espinosa et al. 2016). 
This was demonstrated in a C26-bearing mouse model of cancer cachexia in which 
cancer cachexia was enhanced following supplementation with a combination of 
antioxidants, rich in catechins, quercetin and vitamin C (Assi et al. 2016). Their result 
may have been influenced by the combination of multiple antioxidants or the additive 
dosage, but the results of this thesis confirm MLT’s primary antioxidant capacity 
enhancing effect. 
5.1.4 The role of melatonin in markers of mitochondrial biogenesis; mitophagy fission 
and fusion 
The peroxisome proliferator-activated receptor-γ coactivators (PGC-1) are the master 
regulators of mitochondrial biogenesis. DOX treatment significantly reduced PGC1-α 
protein levels from control levels, whereas MLT pre-treatment restored PGC1-α 
protein levels to control levels (Fig. 4.1.14), which indicates that MLT protects 
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mitochondria which is consistent with literature where MLT was found to restore 
PGC1-α protein levels to control levels in pinealectomized rats (Teodoro et al. 2014).  
PGC-1 coactivators are enriched in tissues such as skeletal muscle which has a high 
capacity for mitochondrial respiratory function (Baar et al. 2002, Pilegaard et al. 2003). 
Growing evidence suggest that PGC-1 signalling plays an important role in skeletal 
muscle structure and function (Lin et al. 2002, Arany et al. 2007, Handschin et al. 
2007), and ROS induced PGC1-α signalling forms a key axis in the regulation of 
skeletal muscle mitochondrial function (Liao 2012). With regard to DOX myotoxicity, 
DOX treatment has been shown to induce an oxidative-to-glycolytic metabolic shift in 
normal skeletal muscle (Fabris and MacLean 2015). In contrast, PGC-1α is implicated 
in muscle fibre-type switching and its over-expression in transgenic mice has been 
shown to increase the proportion of oxidative type I fibres (Zhang et al, 2017). 
Interestingly, MLT has also been shown to modulate PGC1-α signalling in different 
tissue types (Guo et al. 2014, Teodoro et al. 2014, Yu et al. 2017), therefore the effect 
of MLT on PGC1-α expression was investigated during DOX-induced myotoxicity. 
A study conducted by Kavazis et al. (2014) demonstrated that short term endurance 
exercise was protective against acute DOX-induced FoxO transcription in skeletal 
muscle by increasing PGC1-α in the soleus muscle. In support of the findings of this 
thesis, a recent study demonstrated that MLT reduced ROS production, enhanced 
mitochondrial biogenesis and preserved mitochondrial function thus improving 
myocardial ischemia/reperfusion injury in type 1 diabetic rats (Yu et al. 2017). The 
authors concluded that the AMPK-PGC1α-SIRT3 axis was essential in this process. 
In further support of the findings presented here, Teodoro et al. (2014) demonstrated 
that MLT was able to restore mitochondrial function and insulin resistance via 
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activation of CREB- PGC-1α pathway in an in vitro model of insulin resistance in rat 
skeletal muscle primary cells and in vivo in pinealectomized rats.  
Mfn2 is a target of PGC-1α that enhances mitochondrial fusion (Zorzano 2009). Mfn2, 
specifically aids the merger of neighbouring mitochondrial membranes resulting in 
mitochondrial fusion (Papanicolaou et al. 2012) and its decreased expression in 
muscle is associated with cachexia-induced muscle loss (Xi et al. 2016). However, 
literature on fission and fusion events in skeletal muscle is limited and needs to be 
explored further. 
Mfn2 protein expression in the DM group was significantly (* p < 0.05) reduced from 
the average control group’s level (Fig. 4.1.16B). This may indicate that DOX treatment 
decreased fusion and MLT pre-treatment was not able to recover Mfn2 to control 
levels. Previously it was shown that acute administration of DOX (20 mg/kg body for 
24 h) did not alter Mfn2 protein levels in rat soleus muscle (Kavazis et al. 2014). 
Furthermore, in a recent study by Tang et al. (2017) it was found that DOX decreased 
cardiomyocyte Mfn2 expression which stimulated mitochondrial fission and ROS 
production leading to cardiomyocyte cell death. A reduction in Mfn2 may represent 
another mechanism by which DOX potentially induces atrophy since decreased Mfn2 
expression is associated with muscle loss in cancer cachectic mice (Xi et al. 2016). 
No significant differences in Mfn1 protein expression were observed, however the MLT 
group showed a trend (* p < 0.065) toward an increase compared to the DOX group 
(Fig. 4.1.16A). Mfn1 interacts with Mfn2 at the mitochondrial membrane and its 
expression has been shown to increase mitochondrial length and interconnectivity 
(Legros et al. 2002), which might indicate that MLT may aid in promoting mitochondrial 
fusion. 
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Mitophagy in skeletal muscle has been receiving increased attention from researchers, 
especially within the context of muscle atrophy (Wu et al. 2009, Romanello et al. 2010). 
One major pathway of mitophagy is the PINK1/Parkin pathway. PINK1, a 
mitochondrial serine/threonine kinase, becomes stabilized at the outer mitochondrial 
membrane (OMM) following depolarization of the OMM. PINK1 also phosphorylates 
ubiquitin, since Parkin requires ubiquitin ligase activity (Moyzis et al. 2015). PINK1 
next binds to Parkin aiding its translocation to the mitochondria where Parkin 
ubiquitinates mitochondrial surface proteins (Koleini and Kardami 2017). Parkin-
dependent ubiquitination of mitochondrial surface proteins results in their proteasome 
degradation, mitochondrial fragmentation and thus promotes mitophagy (Wrighton 
2011, Moyzis et al. 2015, Saito and Sadoshima 2015). In the current study MLT 
treatment alone significantly (* p < 0.05) increased the mitophagy marker, PINK1 
compared to all other groups, while the DM group remained at control levels (Fig. 
4.1.17). This finding indicates that MLT could potentially enhance mitophagy, which is 
in line with literature where evidence is provided for mitophagy enhancement with MLT 
to promote de novo mitochondrial biogenesis (Tan et al. 2016). Various studies using 
different tissue types have shown that MLT treatment was able to exert protective 
effects by increasing PINK1 protein levels in order to clear damaged mitochondria 
(Kang et al. 2016, Cao et al. 2017). MLT’s ability to increase PGC1- α levels and to 
promote mitophagy relates well with MLT’s anti-anaemic effects discussed in section 
5.1.2, since Pin et al. (2015), showed that mild exercise and treatment with 
erythropoietin prevented atrophy in tumour-bearing mice and that these benefits relied 
on PGC-1α induction and the promotion of mitophagy. 
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5.1.5 The effects of MLT and DOX on muscle degradation processes 
In line with MLT’s oncostatic effects, it is able to induce apoptosis in tumour cells but 
can also inhibit apoptosis in other tissue (Hill et al, 2011, Hu et al. 2016, Proietti et al. 
2013, Sheen et al. 2016, Slominski et al. 2012). It is well established that DOX-induced 
cardiotoxicity results in the loss of cardiomyocytes through cell death pathways. 
Skeletal muscle however is multi-nucleated and the extent to which it is affected by 
cell death mechanisms is debatable, since apoptosis of single cells cannot account for 
the complexity of the programmed death of multinucleated myofibres. Numerous 
articles though reported on myonuclei loss by mechanisms commonly associated 
directly with apoptosis when rodents hindlimbs were suspended (Bennett et al. 2013, 
Hao et al. 2011).  
In the current study, cCaspase3, a marker of apoptosis was significantly increased in 
the DOX only group compared to controls. Although the DOX with MLT co-treatment 
group tended to have reduced cCaspase3 compared to DOX alone, it was not 
significantly different (4.1.8A). No significant differences were observed in the 
apoptotic marker cPARP (4.1.8B). 
Conflicting evidence for DOX-induced cell death has been reported. An acute high 
dose (20 mg/kg body weight) administration of DOX in mice did not change in caspase 
activity over a period of nine days in mixed fibre type gastrocnemius muscle (Campbell 
and Quadrilatero 2016). However, in a similar model of acute high dose DOX 
administration (15 mg/kg body weight), DOX induced DNA fragmentation of myonuclei 
as well as Bax activation in gastrocnemius muscle (Yu et al. 2014). It has been 
demonstrated that MLT decreased the apoptotic marker cCaspase3 in C2C12 
myoblasts exposed to oxidative stress (Kim et al. 2011). In vivo studies further 
confirmed this action of MLT where a significant reduction in cCaspase3 was observed 
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4 days after skeletal muscle contusion injury in MLT supplemented rats (Stratos et al. 
2012). The selective properties of MLT have been demonstrated in studies where 
caspase cleavage was induced in melanoma and breast cancer cells, demonstrating 
its pro-apoptotic ability in cancer cells (Gatti et al. 2017). 
It is hypothesised that muscle fibres maintain their myonuclear domains in conditions 
of atrophy (Tews 2005), where evidence exists that only a subset of myonuclei 
undergo apoptosis during skeletal muscle atrophy, while the muscle fibre remains 
intact (Liu and Ahearn 2001). However this notion has been challenged by 
experiments which demonstrated that myonuclear loss is negligent during atrophy 
where nuclei in the same muscle fibres were monitored in vivo for up to one month. 
The authors provided data that nuclei undergoing apoptosis during atrophy were 
derived from mononucleated stromal or satellite cells, but not myonuclei from the 
muscle fibre (Bruusgaard and Gundersen 2008). Therefore the current thesis research 
also investigated markers of atrophy without apoptosis. 
The effects of Doxorubicin and Melatonin on the Ubiquitin ligases 
The FoxO family of transcription factors is important for MuRF1 and MAFbx gene 
expression, along with other regulators including AMPK and PGC1-α. FoxO1 followed 
a similar protein expression pattern to FoxO3a but no significant differences were 
observed between groups (4.1.9C). FoxO3a protein levels were significantly increased 
in the DOX treated group compared to control and the DM group (4.1.9D). A significant 
increase in the atrophy marker MURF1 was observed in DOX treated groups 
compared to the control group and the MLT only group (4.1.9B), while MAFbx protein 
levels in the DM group were significantly reduced compared to all other groups, 
excluding the DOX treated group (4.1.9A).  
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It has previously been demonstrated that acute exposure (24 h) of rats to DOX (20 
mg/kg) resulted in increased FoxO3, MuRF-1 and BNIP3 expression in soleus muscle 
(Kavazis et al. 2014). It was also demonstrated that DOX administration (15 mg/kg 
body weight, 48 h) resulted in increased mRNA expression of MAFbx and MURF1 in 
skeletal muscle in vivo independent of FoxO activation (Yamamoto et al. 2008). On 
the other hand, both MAFbx and MuRF1 mRNA levels which are normally very high in 
the hindlimb muscle of spinal cord injured rats, decreased in response to the 
exogenous MLT treatment (Park et al. 2012). Similarly, muscle atrophy-related genes, 
MAFbx and MuRF1 were down-regulated in gastrocnemius muscle of MLT-
administered rats after stroke-induced muscle atrophy although only MAFbx at the 
mRNA level was attenuated in the soleus of these rats (Lee et al. 2012). The MURF1 
and MAFbx protein expression patterns are quite different but it is important to note 
that MURF1 and MAFbx transcriptional control is complex and variable expression 
patterns are not uncommon, especially since multiple transcription factors can activate 
these atrogenes (Bodine and Baehr 2014). The results of this thesis seem to indicate 
that DOX may be inducing atrophy via FOX3a activation and subsequently MURF1 
protein levels, while MLT may reduce atrophy signalling by decreasing MAFbx protein 
levels. Downstream from atrophy signalling no significant differences were observed 
in protein levels of two markers of the UPP, namely K48 and K63 (4.1.10).  
Melatonin regulates autophagy   
Phospho-mTOR levels were significantly increased in the DOX group compared to 
control levels (Fig. 4.1.11A). Increased mTOR protein levels are associated with the 
inhibition of autophagy and lysosome biogenesis (Kim and Guan 2015). Moreover, 
p62 protein levels in the DOX group were significantly increased in comparison to the 
DM group which indicates that it is not being cleared through autophagic degradation 
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(Fig. 4.1.11B). LC3-1 to LC3-IIB conversion levels in the DOX group were significantly 
reduced compared to all other groups which is indicative of lack of autophagosome 
formation (Fig. 4.1.11C). These results taken together indicate that the autophagy 
process may have been inhibited by DOX administration in the current study and thus 
potentially resulted in the accumulation of dysfunctional organelles. However, other 
studies have reported that DOX induced upregulation of LC3-II levels (Kobayashi et 
al. 2010), and increased autophagic vacuoles in both mice (Kawaguchi et al. 2012) 
and rats (Wu et al. 2014).  
In contrast, the DM group had significantly reduced protein levels of phospho-mTOR 
and p62 compared the DOX group, while LC3-1 to LC3II-B conversion levels were at 
baseline levels indicating that autophagy was not being inhibited, p62 and its cargo 
were being cleared and autophagy degradation was functional. These findings 
suggest that MLT may prevent skeletal muscle atrophy by regulating autophagy 
positively. But, several other studies have reported that MLT can attenuate autophagy 
in vivo in response to different stressors (Feng et al. 2017, Nopparat et al. 2017, San-
Miguel et al. 2015, Trivedi et al. 2016 and Zhang et al. 2016).  
A number of studies have demonstrated that stimulating autophagy (starvation, 
moderate diet restriction and Rapamycin administration) prior to DOX treatment is 
protective, since this would aid the elimination of dysfunctional mitochondria which are 
a source of ROS (Tal et al. 2009, Lee et al. 2012). Furthermore, data from other in 
vivo models suggested a protective reduction of LC3-II in response to DOX 
administration and showed that autophagy upregulation promoted cardiomyocyte 
survival (Sishi et al. 2013, Bartlett et al. 2016). It was demonstrated in another study 
that DOX was able to block autophagic flux through the prevention of lysosome 
acidification (Li et al. 2016). In the current thesis research autophagic flux was not 
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assessed since the appropriate groups of autophagy inhibitors and inducers were not 
included in the study design.     
DOX treatment increases Calpain-3 protein levels 
Increased intracellular calcium levels activate calpains which cleave important 
structural proteins. Min et al. (2015) designated both mitochondrial ROS generation 
and calpain activation as major contributors to DOX-induced muscle dysfunction. 
Moreover, calpains inhibit autophagy by preventing fusion of lysosomes and 
autophagosomes, and thus the maturation of autophagosomes (Sarkar, 2013). In line 
with literature we found that DOX induced an increase in calpain in this study.  
The protein expression patterns of ubiquitously expressed calpain -1 & -2 were similar 
to that of calpain-3 but no significant differences in ubiquitous calpains were observed 
between groups (Fig. 4.1.12A&B). However a significant increase in calpain-3 protein 
levels was observed in the DOX treated group compared to the MLT treated groups 
(Fig. 4.2.12C). To the best of my knowledge, this is the first evidence suggesting a 
role for calpain 3 activation with DOX treatment. On the other hand, a lack of calpain-
3 results in the most severe phenotypic form of muscle degeneration which is 
characterised by oxidative stress, mitochondrial abnormalities and energy deficits 
(Kramerova et al. 2009). Calpain-3 is thus associated with sarcomeric remodelling and 
maturation following degradation. This result may indicate that the DOX treated group 
may be undergoing early stage regeneration. In many models the effects of DOX-
induced muscle atrophy were studied in acute models, where high doses of DOX were 
administered which gives little information with regard to what happens in a clinical 
setting where patients receive intermittent and lower doses of DOX treatment. Finally, 
it has been shown previously that MLT treatment both in vitro (Suwanjang et al. 2013) 
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and in vivo (Samantaray et al. 2008) attenuated calpain degradation, which is 
consistent with findings in this study.    
5.1.6 Effects of DOX and MLT on muscle regeneration   
Muscle regeneration is an important homeostatic process of the adult skeletal muscle, 
which maintains muscle health throughout life in response to stimuli, such as injury by 
activating muscle satellite cells (Joanisse et al. 2017).       
In the current study satellite cell number (Fig. 4.1.18B) and PAX7 protein levels (Fig. 
4.1.18C) did not decrease from control values with DOX treatment but tended towards 
being slightly higher than control levels (not significant). There was evidence of 
membrane damage as seen by Mb leakage into circulation with DOX treatment and 
membrane damage alone could be a cue for satellite cells to become active. Indeed, 
MyoD (Fig. 4.1.19B) protein levels in the DOX group were significantly higher 
compared to the MLT group suggesting activation. DOX treatment has previously been 
shown to decrease satellite cell number by inducing apoptosis (Bruusgaard and 
Gundersen 2008) which may explain the lack of increase in Pax7+ cells despite 
activation.  
Little evidence exists for MLT’s actions during muscle regeneration following injury but 
an in vivo study showed that MLT may improve muscle regeneration following crush 
injury in rats by increasing satellite cell numbers (Stratos et al. 2012). MLT treated 
groups (MLT and DM) had significantly increased satellite cell numbers (Fig. 4.1.18B) 
and PAX7 protein levels (Fig. 4.1.18C) compared to control groups, indicating 
stimulation of proliferation which is in agreement with the results of Stratos et al. (2012) 
in their muscle crush injury model. But, no differences in protein levels of myogenin 
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(Fig. 4.2.19A) were observed between groups, indicating little or no effect on 
differentiation. 
MLT treatment has been shown to increase IGF-1 levels of satellite cells in an atrophy 
model of rat castration (Oner et al. 2008), as well as IGF-1 receptor expression in a 
model of atrophy subsequent to stroke (Lee et al. 2012). IGF-1 is a positive regulator 
of both proliferation and differentiation of skeletal muscle cells (Miyake et al. 2007). In 
reviews by Kurabayashi et al. (1993 and 1994) it was discussed that MyoD and 
myogenin gene transcripts decreased in C2C12 myoblasts following DOX exposure. 
Furthermore, it has been determined previously that MyoD is directly involved with 
DNA repair following genotoxic stress (Kobayashi et al. 2004) which could explain the 
higher protein levels of MyoD observed in the DOX group compared to MLT group. 
ROS levels have been shown to increase with age (Romano et al. 2010) and 
conversely MLT has been shown to decline with age (Hardeland 2012, Song et al. 
2016). Increasing evidence shows that MLT protected against age-related 
mitochondrial oxidative damage (Song et al. 2016). Sarcopenia is the gradual 
degenerative loss of skeletal muscle mass with aging and is associated with reduced 
satellite cell number (Coto-Montes et al. 2016). In a recent review by Coto-Montes et 
al. (2016) the authors speculated that MLT may be able to increase satellite cell 
number and improve regenerative processes in the sarcopenic condition. The current 
result showed that MLT may increase satellite cell number (4.1.19) after DOX-induced 
skeletal muscle atrophy.  
Studies that have investigated the effects of MLT on satellite cells and skeletal muscle 
regenerative processes remain limited. However, the protective and regulatory effects 
of MLT on the drive to commitment and differentiation of mesenchymal stem cells 
(MSCs) into osteogenic, chondrogenic, adipogenic or myogenic lineages may provide 
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some insight (Luchetti et al. 2014). A role for MLT in the control of survival and 
differentiation of mesenchymal stem cells (multipotent progenitor cells capable of 
transdifferentiating into various cell lineages and primarily involved in developmental 
and regeneration processes) has been proposed (Luchetti et al. 2014). MSCs possess 
strong paracrine capacity by secreting cytokines and growth factors capable of 
suppressing the immune system, inhibiting fibrosis and apoptosis, augmenting 
angiogenesis and stimulating differentiation of tissue specific stem cells (Gnecchi and 
Melo 2009). MLT has been shown to confer cell protective and regulatory effects in an 
array of immune and non-immune cell subsets (Luchetti et al. 2010). These effects are 
believed to extend to MSCs as well, since MLT pre-treatment of MSCs in an ex vivo 
model of ischemic kidney injury promoted the secretion of proangiogenic/mitogenic 
factors and prevented cell apoptosis (Mias et al. 2008). Moreover, it has been revealed 
that MSCs express MLT-receptors on their surface further strengthening support for 
the role of MLT as a protective factor for MSCs (Radio et al. 2006, Mias et al. 2008, 
Sethi et al. 2010, and Wang et al. 2013). It was also demonstrated that MLT protected 
MSCs following exposure to H2O2 (Mias et al. 2008). Specifically, acting via the MLT 
receptors it conferred anti-apoptotic activity and regulated MSC antioxidant genes. 
This was achieved by MLT inducing the overexpression of the antioxidant enzymes 
catalase and superoxide dismutase‐1. These effects of MLT on MSCs were confirmed 
by studies which showed that transplanted MSCs were protected against oxidative 
stress in the microenvironment of injured tissue (Liu et al. 2013, Wang et al. 2013).        
5.1.7 Effects of DOX and MLT on sirtuin levels 
DOX cardiotoxicity studies showed that SIRT1 down-regulation is accompanied by cell 
apoptosis and increased oxidative stress both in vitro and in vivo (Ruan et al. 2015, 
Sin et al. 2015, Du et al. 2017). Furthermore, it is becoming evident that MLT is 
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potentially modulating expression and/or activity of SIRTs, which is the subject of a 
recent review by Mayo et al. (2017). However, there are no studies to my knowledge 
where the role of MLT on SIRT activity in the context of DOX-induced myotoxicity has 
been investigated.  
In the current study, mitochondrial specific SIRT3 protein levels were significantly 
increased in DOX treated (DOX and DM) groups (Fig. 4.1.20B). While, SIRT1 levels 
remained relatively unchanged (Fig. 4.2.20A). Cheung et al. (2015), demonstrated that 
SIRT3 protein overexpression attenuated DOX-induced ROS production in vitro and 
could thus potentially be used as therapy for DOX-induced cardiac dysfunction. 
Moreover, SIRT3 was found to attenuate DOX-induced cardiac hypertrophy, 
mitochondrial dysfunction (Du et al. 2017) and cardiomyopathy in mice (Pillai et al. 
2017). Sin et al. (2016) demonstrated that DOX-induced myotoxicity in aged skeletal 
muscle was alleviated via SIRT1-dependent mechanisms following acute resveratrol 
treatment. In another acute model (20 mg/kg for 24 h) of DOX-induced myotoxicity, 
F344 rats were administered DOX and immediately starved of water and food for 24 
hrs. Treatment did not affect the expression of SIRT1 and SIRT3 in soleus muscle of 
fasted animals which is in contrast to the aforementioned studies (Dirks-Naylor et al. 
2013). In the current study, increased SIRT3 protein levels in the DOX treated groups 
may represent a form of compensatory adaptation by mitochondria to increase SIRT3 
protein levels to combat DOX myotoxicity, perhaps in an attempt to increase PGC1-α 
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5.2 In vitro study  
The current data revealed that DOX acted directly on differentiated C2C12 myotubes 
to decrease myotube width, and that this change was preceded by a rise in 
mitochondrial ROS. By treating the increase in ROS using MLT as antioxidant, DOX-
stimulated myotube atrophy was attenuated. These findings identify a causal role for 
free radical mediated signalling in DOX-induced catabolism. 
DOX and muscle catabolism 
 In the clinical setting, muscle atrophy is a significant contributor to mortality in cancer 
patients (Burckart et al. 2010). This state of catabolism remains while patients undergo 
treatment, affecting muscle function and resulting in poor quality of life (Knobel et al. 
2001). Skeletal muscle atrophy is evident in patients receiving DOX treatment (Bonifati 
et al. 2000, Tozer et al. 2008), an effect recognised in in vivo models of chemotherapy 
(McLoon et al. 1998, Falkenberg et al. 2002, Gilliam et al. 2011). Here, a similar 
catabolic response in C2C12 myotubes was observed following DOX exposure. The 
present study adds to literature and demonstrates that direct exposure to DOX 
reduces myotube size. 
DOX-induced mitochondrial ROS 
DOX, an anthracycline, is highly effective against a variety of solid tumours but is 
limited by cytotoxic side effects on non-cancerous tissue via oxidative stress (Gilliam 
and St Clair 2011). It has been shown to increase ROS in both cardiac and skeletal 
muscle (Doroshow 1983, Gilliam et al. 2011, Smuder et al. 2011). The mitochondria 
are believed to be the main source of DOX-induced free radicals and to constitute the 
main source of superoxide anion in most tissues (Yen et al. 1996, Turrens 2003, 
Chandran et al. 2009). In a recent study where the progression of cancer cachexia 
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over time in a tumour bearing mouse model was investigated, the authors showed that 
ROS levels increased after a week of tumour inoculation and that mitochondrial 
dysfunction preceded the cachectic phenotype (Brown et al. 2017). DOX accumulates 
in the inner mitochondrial membrane (IMM), where it can be reduced by complex I of 
the electron transport chain into an unstable semiquinone. When oxidized, an electron 
is transferred to oxygen producing superoxide anion (Davies and Doroshow 1986, 
Chen et al. 2007, Monsuez et al. 2010). In the current study mitochondrial specific free 
radical activity was found to be significantly elevated in C2C12 myotubes following 
DOX exposure, providing evidence for the mitochondria as a potential source of ROS. 
Exposure of myotubes to MLT, a naturally produced antioxidant, inhibited the increase 
in superoxide levels caused by DOX. Interestingly, the inhibition of MT1 receptor by 
luzindole, did not alter superoxide levels from control levels, indicating that MLT was 
still able to confer protection. This could be due to the following reasons: 1) luzindole 
is mainly a MT1 receptor antagonist and only partial inhibitor of the MT2 receptor, thus 
MLT could be reducing ROS via MT2 receptor signalling; 2) due to MLT’s amphiphilic 
properties it is capable of directly crossing lipid bilayers and could thus exert its effects 
in this way (Nosjean et al. 2001), since MLT’s biological activity may be mediated via 
non-receptor mediated antioxidant activity (Dubocovich et al. 2003 & 2010); or/and 3) 
MLT may be reducing free radicals through the formation of its metabolites, which are 
also potent antioxidants.  
Furthermore, there are three potential mechanisms by which MLT can decrease 
mitochondrial ROS production. The chemical backbone of the MLT molecule contains 
an indole moiety which interacts with oxidants, giving the molecule the capability to 
directly scavenge hydrogen peroxide, as it accumulates in the IMM (Szeto and Schiller 
2011). MLT has been shown to promote mitochondrial respiration, which can reduce 
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ROS formation by increasing ATP production (Reiter et al. 2002). Finally, MLT 
attenuates the depolarization of mitochondrial membrane potential and the release of 
the apoptotic initiator protein cytochrome c, which is an enzyme of the electron 
transport chain. Cytochrome c release decreases ATP synthesis and increases 
electron leak, resulting in ROS production (Szeto and Schiller 2011) from the inner 
mitochondrial membrane (Wang et al. 2011).  
The disruption of oxidative stress can induce catabolic signalling and protein 
degradation in skeletal muscle (Moylan and Reid 2007). MLT, which has a high affinity 
for mitochondria where it accumulates in high concentrations (Tan et al. 2016), 
negated changes caused by DOX, thus preserving myotube size by stabilizing 
cytosolic anti-oxidant activity. This finding suggests that increased mitochondrial ROS 
may cause DOX-induced atrophy. 
Sirtuins 
SIRT3, a NAD+ dependant deacetylase, is the main mitochondrial specific protein 
deacetylase (Lombard et al. 2007) and is expressed in response to fasting or caloric 
restriction (Shi et al. 2005, Palacios et al. 2009, Hallows et al. 2011). SIRT3 
deacetylates numerous mitochondrial enzymes to coordinate metabolic alteration and 
regulate mitochondrial respiration and oxidative stress resistance (Cheung et al. 
2015). SIRT3-deficient mice presents with significantly reduced tissue ATP levels (Ahn 
et al. 2008), and are also vulnerable to cardiac hypertrophy (Sundaresan et al. 2009, 
Hafner et al. 2010). A recent review by Mayo et al. (2017) describes the MLT/SIRT 
interaction as dichotomous since different actions may be affected in normal and in 
cancer cells. The function of SIRT3 in skeletal muscle, however is not well 
characterized.  
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In the current in vitro study SIRT3 was significantly increased in the DOX (consistent 
with the in vivo result, Fig. 4.1.20B) and MI groups compared to control levels (Fig. 
4.2.4). Cardiotoxicity studies have shown that increased SIRT3 expression attenuated 
DOX-induced oxidative stress and improved mitochondrial respiration (Cheung et al. 
2015). Moreover, the overexpression of SIRT3 protected mice from DOX-induced 
cardiomyopathy by preventing mitochondrial DNA damage (Pillai et al. 2016). SIRT3 
levels could be increased in the DOX group as compensatory mechanism to protect 
the mitochondria from DOX-induced free radical damage (Jing et al. 2011) and to 
preserve skeletal muscle oxidative capacity (Lin et al. 2014), since DM group was not 
changed from control levels (4.2.4). SIRT3 expression has been shown to be 
increased in response to fasting (Cheung et al. 2015) which could be another reason 
why SIRT3 levels are increased in the DOX group since DOX treated animals reduced 
their food and water intake by more than half within the 24 h period following initial 
administration, a behaviour which persisted for several days (Dirks-Naylor et al. 2013). 
On the other hand, in an attempt to better regulate mitochondrial energy production 
efficiency, SIRT3 may be contributing to myotube atrophy since a previous study has 
reported a 30% reduction in muscle mass via transgenic expression of SIRT3M3 (an 
isoform of SIRT3) in skeletal muscle (Lin et al. 2014). They found that SIRT3 regulated 
the formation of oxidative muscle fibres, enhanced muscle metabolic function, and 
decreased muscle mass (Lin et al. 2014). SIRT3 however, may have different 
functionalities via its other protein isoforms, SIRT3M1 and SIRT3M2. The finding that 
SIRT3 can reduce muscle mass, could also be the reason why its protein levels are 
significantly increased in the MI group (4.2.4) which suggests that MLT may be 
regulating SIRT3 expression via the MT1 receptor. This has previously been shown in 
hepatoxicity studies where MLT upregulated SIRT3 via MT1 receptor-PI3K/AKT-PGC-
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1α signalling pathway (Song et al. 2017) and SIRT3 inhibition blocked protective 
antioxidant effects of MLT in hepatocytes (Chen et al. 2015, Pi et al. 2015). MLT’s 
ability to influence mitochondrial sirtuin activity is a relatively unexplored research field 
in relation to skeletal muscle which may provide interesting new therapeutic avenues. 
Autophagy 
Due to the interesting in vivo findings on MLT’s role in mediating the autophagy 
process, it was decided to investigate autophagic flux in vitro. The CYTO-ID 
fluorescent detection kit was used to assess autophagic flux. The assay weakly labels 
lysosomes and assesses both autophagosome and autolysosomes, further down the 
autophagic process. An increase in fluorescent signal indicates both autophagosomal 
and autolysosomal abundance which is usually the case if there is autophagy or 
lysosomal dysfunction. 
Basal autophagic flux seemed to be present in all groups (Fig. 4.2.5) since chloroquine 
levels were increased compared to control levels. Hence, all groups displayed 
functional autophagy, with no autophagy dysfunction due to the treatment intervention. 
The DOX (** p < 0.01) and DM (* p < 0.05) treatment groups had significantly greater 
levels in the chloroquine compared to control group, therefore, these cells had high 
and functional autophagic flux. The rapamycin+chloroquine group was not significantly 
higher compared to the chloroquine group, suggesting that rapamycin treatment had 
not further increased flux. This indicates that either the cells were not majorly 
responsive to rapamycin treatment (different rapamycin concentrations and incubation 
times) or their basal flux was (due to the treatments) already so high that it could not 
increase further. Li et al. (2016) demonstrated that autophagy flux is blocked due to 
DOX treatment in cardiac muscle of mice and in cardiomyocytes in culture. The 
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authors observed the inhibition of flux was accompanied by an increase in undegraded 
autolysosomes. In the same study no alteration in autophagic flux was found in DOX 
treated C2C12 skeletal muscle myoblasts. This result is similar to what was observed 
in this thesis research in C2C12 myotubes. To further make conclusions on the 
autophagy flux data, protein levels of key autophagy markers together with appropriate 
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Chapter 6: Summation  
In summary, the studies in this thesis clearly demonstrated the detrimental effects of 
DOX on skeletal muscle. In particular, sarcolemma damage was demonstrated 
indirectly by leakage of Mb into circulation; calpain homeostasis was altered and 
atrogenes activated.  However, administration of MLT provided effective treatment and 
allowed for elucidation of possible mechanisms involved in the detrimental effects of 
DOX.  
Possible mechanisms of DOX-induced protein degradation and MLT-induced 
protection 
As DOX enters the cell it accumulates in the nucleus, mitochondria and cell 
membrane. In the nucleus and mitochondria, it intercalates with DNA and interferes 
with topoisomerase-II-mediated DNA repair thus increasing cell death. DOX is further 
oxidized to an unstable metabolite and again converted to DOX in a process which 
generates reactive oxygen species. ROS can then damage myocyte membranes 
which results in the leakage of proteins such as Mb into circulation. 
Moreover, ROS can damage organelles such as the mitochondria and sarcoplasmic 
reticulum via lipid peroxidation, further damaging DNA, increasing oxidative stress and 
triggering apoptotic pathways. Damage to mitochondria and the sarcoplasmic 
reticulum may result in the leakage of calcium ions into the cell; free cytosolic calcium 
in turn activates degradative calpains which further damages the sarcolemma and 
triggers myofibrillar damage. ROS signalling may also dephosphorylate FoxO 
transcription factors by modifying protein kinases or modulating phosphatases, which 
then translocate to the nucleus where it transcribes atrogenes and impairs autophagy 
degradation. These processes then lead to protein degradation and muscle wasting.    
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Figure 6.1: Proposed signalling cascade in DOX and ROS mediated mechanisms of skeletal atrophy and MLT 
protection as described in this study. Abbreviations: Mb, myoglobin; DOX, doxorubicin; MLT, melatonin; MURF-1, 
muscle ring-finger 1; ROS, reactive oxygen species; Ca2+, calcium; SR, sarcoplasmic reticulum; LPO, lipid 
peroxidation; FoxO’s, Forkhead box O. 
MLT and its metabolites are potent antioxidants and act to decrease ROS production 
to prevent membrane damage and protein leakage, by inhibiting mitochondrial 
damage and dysfunction, resulting in a nett increased mitochondrial biogenesis. Free 
cytosolic calcium ions are reduced due to the protection of mitochondria and the 
sarcoplasmic reticulum which then attenuates calpain activation and myofibrillar 
damage. MLT also prevents cytosolic FoxO from being dephosphorylated by 
intervening in ROS signalling and may thus reduce transcription of atrophy proteins 
and decrease autophagy degradation and apoptosis. Furthermore, MLT attenuated 
skeletal muscle atrophy by reducing cell apoptosis and increasing satellite cell 
number.  
Based on the literature and the research of this thesis it is worth investigating the 
effects of MLT supplementation with the aim of attenuating skeletal muscle atrophy in 
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cancer patients. It is however, important to do so in a relevant model. The results of 
the current study indicate that exogenous MLT supplementation can inhibit skeletal 
muscle wasting induced by DOX in a pre-cachectic tumour-bearing rat model.   
The prevention of cancer cachexia remains a challenge and only a few drug therapies 
have been demonstrated to be beneficial. MLT supplementation to cancer patients is 
a low cost; low risk intervention. It is time that clinicians, researchers and policymakers 
give increased attention to the beneficial effects of MLT and translate this considerable 
body of experimental, epidemiological, and clinical evidence into further clinical trials 
and ultimately clinical practice. 
Limitations and recommendations for future studies 
Two limitations of the in vivo research include not having measured muscle function 
which would have added great value to the thesis and that tumour effects could not be 
described since cancer cachexia was not achieved. Therefore it is unclear what effect 
the cancer contributed to the cellular effects described. A significant decrease in CSA 
of type 1 muscle fibres of the gastrocnemius muscle in the TCON group was however 
observed. This may indicate the start of metabolic alterations and thus pre-cachexia. 
Furthermore, food intake could also have added value to the study. 
Furthermore, limitations of the in vitro model included not using and inhibitor of the 
MT2 receptor, since Luzindole is only a partial inhibitor of the MT2 receptor. The study 
could further have benefited from the addition of a Luzindole only control group to 
probe whether Luzindole alone had any effects on C2C12 myotubes. 
Future studies should include measures of muscle function and food intake. Moreover, 
a different rodent model in which cancer cachexia has been established should be 
used in combination with DOX treatment in order to assess whether MLT confers 
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protection to skeletal muscle. Clinical trials should next be considered due to the 
burden of DOX-induced muscle toxicity in cancer patients and the safe and cost-
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